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Abstract 
 
Protein kinases are key regulators of most biochemical pathways and their 
involvement in different diseases is extensively documented. To identify the 
protein substrates of kinases is therefore of great importance for elucidating their 
functional role in the cell and to develop disease-specific therapies. However, the 
identification of specific kinase substrates is highly challenging due to the large 
number of protein kinases in cells, their substrate specificity overlap and the lack 
of absolute specificity of inhibitors. In the late 90s, Shokat and coworkers 
developed a protein engineering-based method addressing the question of 
identification of substrates of protein kinases. The approach was based on the 
mutagenesis of a specific residue to enlarge the ATP binding pocket of the target 
kinase to accommodate a chemically modified ATP as co-substrate, which would 
not bind to the native kinase. One of the challenges in applying this method to 
other kinases is to identify the optimal combination of kinase binding pocket 
mutations and ATP analogues such that the ATP analogue acts as specific co-
substrate for the engineered kinase. Furthermore, the engineered kinases have to 
remain catalytically active.  
This work aims to develop a computational protocol for the engineering of protein 
kinases. We predict which residues within the binding pocket of the target kinase 
could be mutated to change its co-substrate specificity from ATP to an ATP 
analogue. The protocol explores pairings of potential mutations and ATP 
analogues and can be used as prescreening test in the wider experiment for 
identifying specific substrates of protein kinases.  
The protocol was tested on different tyrosine and serine/threonine protein kinases 
from the scientific literature where Shokat’s method was applied and experimental 
data were available. The method correlates well with published experimental data 
available for the tested protein kinases. Subsequently, we applied the 
computational protocol to the Mycobacterium tuberculosis protein kinase G, Mtb 
PknG. Mtb is a pathogenic bacterium and is the causative agent of tuberculosis. 
Tuberculosis is a widespread infectious disease which causes around two million 
deaths per year. PknG plays a key role in the survival of Mtb within the host 
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organism. Since its specific downstream substrates as well as its mechanism of 
action are still unknown, PknG is an attractive target for our computational 
approach. Our protocol allowed us to design a number of pairs of PknG mutants 
and ATP analogues. The most promising pairs were tested in vitro, in our 
laboratory. All in vitro tests were performed by Mohamed-Ali Mahi. The most 
interesting pair was then used in follow-up ex vivo experiments, performed by the 
group of Prof. J. Pieters at Biozentrum. 
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1 Introduction 
 
1.1 Protein engineering 
 
Proteins perform a vast array of functions in cells. They act as enzymatic 
catalysts, transport materials across cell walls and have structural, sensory and 
regulatory functions. Protein engineering is a widely used tool in many fields. It 
allows for investigation of protein functions, for the construction of proteins with 
new and/or improved functions and for increasing protein stability and 
functionality. In the last two decades, computational methods for protein 
engineering have been developed and used to achieve significant findings in 
different fields such as pharmaceutics, synthetic biology and industrial production 
[1-5]. They are used to design novel biocatalysts, such as the O2-dependent 
phenol oxidase able to catalyze a phenol oxidase reaction [6], to design proteins 
with an improved binding affinity and specificity, like the case of a series of 
antibody Fc variants with optimized affinity and specificity for cell surface Fc 
receptors [7], and to design proteins able to bind non-natural cofactors, such as a 
four-helix bundle protein that selectively binds to the nonbiological DPP-Fe(III) 
cofactor [8]. Computational protein engineering methods are organized into two 
main categories, rational design and de novo design [3] (Figure 1.1). The rational 
design approach requires sequence and structural information. Multiple sequence 
alignments (MSA), three-dimensional (3D) structures and 3D structure predictions 
are the best tools to extract significant information such as key residues, 
functionally sites and correlated mutations. All those tools can be used individually 
or in combination to generate engineered proteins (Figure 1.1, left part). De novo 
design refers to the generation of novel protein folds and/or enzymatic activities. 
Such approaches consist of four steps, modelling of the theozyme (that is a 
computational model of the transition state, TS, of a specific reaction including key 
amino acids), searching for a protein scaffold, energy minimization to remove 
possible TS-catalytic residues clashes and selection of design models for 
experimental validation (different factors can be used for selection, such as ligand 
binding energy) (Figure 1.1, right part). In the field of de novo design, the 
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ROSETTA enzyme design protocol developed in Baker’s laboratory [9] is a 
milestone and is the most widely used tools for de novo protein engineering.  
 
 
Figure 1.1. The two main approaches in protein engineering, rational design and de novo 
design. 
 
 
Recent work has demonstrated that computational protein engineering methods 
can generate active catalysts [10-12]. For instance, Jiang and coworkers 
designed new enzymes able to catalyze retro-aldol reactions [11]. To evaluate the 
accuracy of the design models, they solved their structures by x-ray 
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crystallography. The crystal structure of the retro-aldolase 22, RA22, shows that 
the catalytic residues (Lys159, His233 and Asp53) superpose well on the design 
model and the rest of the active site is nearly identical to that one of the design 
model (Figure 1.2). To evaluate the functionality of design models, they monitored 
the retro-aldolase activity via a fluorescence-based assay and the design RA22 
shows a retro-aldolase activity.  
 
 
Figure 1.2. (From [11]) Superposition of the binding site residues of the crystal structure 
(green, PDB: 3HOJ) and designed model (purple) of the RA22 in complex with its 
substrate (4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone, gray stick). The C          
root-mean-square deviation (rmsd) is 0.62 Å. 
 
 
Nevertheless, there are some aspects of computational methods that need to be 
improved, such as the prediction of protein-ligand binding affinities. The predicted 
binding affinities are generally modest or even undetectable when measured 
experimentally [13, 14]. Schreier and coworkers [13] worked on designing models 
of variants of the arabinose-binding protein (ABP). One of those models was 
reported to bind to serotonin (Stn) and was called Stn.A2. They solved the 
structure of Stn.A2 bound to Stn and compared it with the computational model. 
The binding pockets of the structure and the model show high similarity with an 
overall atom rmsd of 0.79 Å (Figure 1.3 A). Although the conformation of the 
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protein resembles the model, the binding of the ligand to the protein was not 
experimentally confirmed. Isothermal titration calorimetry, ITC, was used to probe 
the ligand binding affinity of the designed model. It works by measuring the heat 
that is released during a binding process. While ABP binds to its specific ligand, 
no significant change in heat upon addition of Stn could be detected in the case of 
Stn.A2 (Figure 1.3 B). The analysis performed by Schreier and coworkers shows 
the importance of direct validation of the predicted protein-ligand interactions as 
well as the significant role of the experimental testes as instrument to improve 
computational methods.  
 
 
Figure 1.3. (From [13]) A) Superposition of binding site residues of the crystal structure 
(blue, PDB: 5ABP) and the design model (orange) of Stn.A2 in complex with Stn. B) ITC 
measurements for ABP and Stn.A2. ITC shows that binding occurs for AP but not for the 
designed Stn.A2. 
 
 
1.2 A protein engineered-based method for protein kinases 
 
The identification of the direct substrates of protein kinases is of great importance 
for elucidating the functional roles of these enzymes in cells. However, the 
identification of specific kinase substrates is highly challenging due to the large 
number of protein kinases in cells, their substrate specificity overlap and the lack 
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of absolute specificity of inhibitors [15, 16]. In 1997, Shokat and coworkers 
developed a protein engineering-based method to solve this important issue in 
molecular biology [17]. They used the prototypical viral proto-oncogene tyrosine 
protein kinase Src (v-Src) and engineered its ATP binding pocket by mutating 
residue Ile338 into Gly (residues are numbered as in PDB structures). The single 
point mutation enlarged the binding pocket making a hydrophobic region behind 
the ATP binding pocket accessible to    ATP-competitive ligans with non-polar 
groups at the N6 position of the adenine base. The engineered v-Src preferentially 
used the N6-(benzyl) ATP as phosphodonor. The use of a N6-(benzyl) ATP with a 
radiolabeled  phosphate, -32P, resulted in the v-Src substrates being specifically 
radiolabeled and identified in presence of other protein kinases and all other 
kinase substrates (Figure 1.4) [18, 19]. This approach allowed the identification of 
cofilin and calumenin as specific substrates of v-Src [20]. The residue that controls 
the access to the hydrophobic region beyond the ATP binding pocket, Ile338 in v-
Src, is called ‘gatekeeper’ residue. The Shokat method is based on the ‘bump-
and-hole’ model [21, 22]. The gatekeeper residue is substituted with a small 
amino acid generating a ‘hole’ within the ligand-binding site that can accept 
ligands with bulky substituent groups, ‘bumps’, that sterically clash with the wild-
type binding pocket. The conservation of the ATP binding site between different 
protein kinases makes the approach widely applicable for identifying specific 
kinase substrates. In a similar approach, kinases were engineered to bind 
specifically modified inhibitors [23-29]. 
 
 
1.3 Serine/threonine and tyrosine protein kinases: structure and 
mechanism 
 
The activity of many proteins in cell is regulated by phosphorylation, a reversible 
covalent modification. Protein kinases are the enzymes that catalyze 
phosphorylation reactions and are key regulators of most biochemical pathways 
by phosphorylating a single protein or several closely related proteins in cells [30].  
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Figure 1.4. (From [19]). Schematic representation of the method developed by Shokat 
and coworkers in 1997. Empty ovals represent substrates of protein kinases, red ovals 
represent kinase domains and other colored ovals represent regulatory domains. A*TP is 
the [-32P] N6-(benzyl) ATP (red P is -32P). Y and S are tyrosine and serine that are 
phosphorylated by ATP (black P) or ATP analogue (red P).  
 
 
They constitute one of the largest protein families known (more than 100 proteins 
in yeast and more than 550 in humans). The majority of serine/threonine and 
tyrosine kinases share a bilobal kinase domain fold [15, 31]. The N-lobe is formed 
by five -strands and a single -helix whereas the C-lobe is predominantly          
-helical (Figure 1.5) The C-lobe contains the activation segment, typically 
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composed of 20-30 residues, and the catalytic loop. The activation segment 
contains the activation loop, that activates protein kinase when a specific residue 
(usually Tyr or Thr) is phosphorylated, and the loop that is involved in substrate 
binding [32, 33]. The catalytic loop contains a highly conserved Asp that has a 
significant role in the phosphorylation reaction. It acts as catalytic base to free up 
the hydroxyl oxygen of a Ser, Thr or Tyr on the protein substrate. The 
deprotonated residue is involved in a nucleophilic attack on the terminal 
phosphoryl group (PO32-) of ATP [15].  
The kinase domain exists in two main conformations, active and inactive (Figure 
1.6). In the active conformation the two lobes are close to each other and the 
activation loop is phosphorylated in an open and extended conformation that 
allows substrate binding.  
 
 
Figure 1.5. Ribbon representation of the inactive kinase domain of the human cyclin-
dependent kinase 2 (Cdk2, PDB: 1HCK). ATP is represented as stick and the Mg2+ ion as 
a pink sphere. The activation segment is represented in orange, the catalytic loop in 
green, the P loop in magenta and the hinge region in cyan. The Tyr belonging to the 
activation loop and the Asp belonging to the catalytic loop are represented as sticks. 
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Figure 1.6. Schematic representation of the equilibrium between active and inactive 
conformations of a kinase domain. Activation loop is represented in orange. 
 
 
In the inactive state the two lobes are far apart, the activation loop is 
unphosphorylated and in a closed conformation that sometimes folds into a short 
helix [34, 35]. The ATP is bound in a cleft between the two lobes that are 
connected by a short segment called the hinge region [36]. When ATP occupies 
the ligand-binding site, the phosphates are in part coordinated by the glycine-rich 
loop that is also known as the phosphate binding loop (P loop). The P loop 
contains the conserved motif GXGXG where G is Gly, X is any amino acid and 
 is usually Tyr or Phe. Glycines make the P loop flexible allowing it to approach 
the phosphates of ATP and to bind them via backbone interactions [33, 37]. As 
previously mentioned, ATP acts as phosphodonor in diverse biochemical 
pathways catalyzed by protein kinases (Figure 1.7 A) and the ATP binding site is 
made up of five areas (Figure 1.8 A) [38, 39]. The adenine ring of ATP occupies 
the adenine region and makes favorable hydrophobic interactions with 
hydrophobic residues below and above the adenine plane. In addition, the 
adenine base contains an H-bond donor at position N6 and an H-bond acceptor at 
position N1. In serine/threonine and tyrosine kinases those two atoms are 
involved in two H-bonds generally described by a tri-residue Ni-Oi-2 motif. The 
atom N1 forms an H-bond to the backbone N of the ith residue and the atom N6 
forms an H-bond to the backbone O of the (i-2)th residue [40, 41]. Sometimes, the 
C2 position of adenine acts as H-bond donor and is involved in a weak interaction 
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with a hinge region residue (Figure 1.8 A) [40]. The N6-Ni and N1-Oi-2 H-bonds are 
highly conserved in almost all serine/threonine and tyrosine protein kinases. Due 
to their highly directional nature, the H-bonds between the protein kinase and the 
adenine moiety strongly influence the position and the orientation of the planar 
adenine ring within the adenine region.  
 
 
Figure 1.7. A) Two dimensional (2D) structure of ATP. B) Two isomeric forms of the  
ATP-Mg2+ complex. The divalent cation can be coordinated by  and  phosphates 
(structure on the left) or by  and  phosphates (structure on the right). 
 
 
The ribose ring occupies the sugar region that is mostly polar. Either ribose 2' or 3' 
hydroxyls groups (OH) are involved in one H-bond within the sugar region. Babor 
and coworkers had analyzed the ribose-protein polar interactions in a dataset of 
ATP, ADP and FAD in complex with poteins concluding that water molecules play 
a crucial role in those interactions [42]. Generally, 2'OH or 3'OH interact with the 
oxygen atom of a water molecule which, in turn, interacts with a protein residue 
within the sugar region. In Cdk2 the 2’OH forms an H-bond with a water molecule 
that, in turn, interacts with the side chain of Asp86 (Figure 1.8 B). The ribose ring 
is not planar, quite flexible and can assume different conformations. In addition, 
the orientation is not conserved because of diverse torsion angle values at bonds 
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connecting it to phosphates and adenine (5'CH2C4'and C1'N9, Figure 1.7 A) 
[43]. 
 
 
Figure 1.8 A) (From [39]) Schematic representation of ATP binding pocket regions. 
Dashed black lines represents hydrogen bonds. The five regions are: adenine region 
(cyan), sugar region (green), phosphates region (violet), buried region (blue) and solvent 
accessible region (yellow). B) Cdk2 binding site in complex with ATP-Mg2+ (PDB: 1HCK). 
For simplicity only hinge region residues (80-83), amino acids involved in interactions with 
the ligand (K33, D145 and D86) and water molecules belonging to the binding site are 
represented. Mg2+ is represented as pink sphere and red dashed lines represent 
interactions of the bivalent cation with ATP and protein. Black dashed lines represent     
H-bonds and the purple dashed line the interaction between Lys33 and the  phosphate. 
 
 
The phosphates region contains the P loop and two residues (a Lys and an Asp) 
that play an important role in the catalytic activity and are conserved in almost all 
serine/threonine and tyrosine protein kinases [44]. Lys interacts with the  
phosphate or with both the  and  phosphates. Its role is facilitating the transfer 
of the PO32- group without influencing the binding of ATP. In Cdk2 the catalytic 
Lys is Lys33 that interacts with the  phosphate (Figure 1.8 B). To understand the 
role of the conserved Asp in the phosphates region, it is firstly essential to 
illustrate the function of divalent metal ions, such as Mg2+ or Mn2+, in the catalytic 
activity of protein kinases. Kinetic studies had revealed that protein kinases are 
essentially inactive in absence of divalent cations within the binding site [30]. The 
divalent ion is not part of the binding pocket but the complex of a metal ion and 
B 
F80 
E81 
F82 
L83 
K33 
D145 
D86 
A 
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ATP is the true substrate of the protein kinase. The divalent ion, often Mg2+, 
chelates the  and  phosphates or the  and  phosphates of ATP (Figure 1.7 B). 
It is important for diverse reasons. First of all, it neutralizes the negative charge of 
the phosphates limiting electrostatic repulsions. Moreover, the interaction between 
the ion and the phosphates hold the nucleotide in a well-defined conformation with 
the terminal phosphate correctly placed for the transfer to the substrate. The 
strictly conserved Asp interacts with the essential divalent ion assuming a 
significant role in the kinase catalytic activity [30, 44, 45]. In Cdk2 the catalytic Asp 
is Asp145 and it interacts with Mg2+ (Figure 1.8 B). The phosphate moiety can 
assume different conformations within the phosphates region because of diverse 
torsion angle values at bonds connecting phosphate and oxygen atoms. 
Moreover, the presence of one or two divalent cations can also influence the 
conformation assumed by the phosphates. The solvent accessible area is a 
hydrophobic slot open to the solvent and it is not occupied by ATP. The buried 
region is a hydrophobic region located in the back of the ATP pocket and it is not 
used by ATP. The size and the shape of the buried region are controlled by the 
first amino acid of the hinge region. In 73% of human kinases a hydrophobic 
amino acid with a bulky side chain (Met, Phe or Leu) is observed at that position, 
22% have a small residue, such as Thr or Val and the remaining 5% has one of 
the other amino acids [38, 39, 46, 47]. This amino acid acts as a ‘molecular gate’ 
controlling the accessibility to the buried region, indeed a residue with a large side 
chain effectively ‘closes the gate’ making the buried region inaccessible. For that 
reason, this residue has been termed the ‘gatekeeper’ residue [19, 48-50]. 
 
 
1.4 Protein-ligand interaction 
 
Most biological processes rely on the mutual recognition of proteins with their 
specific ligands. Selective protein-ligand binding is governed by two main factors: 
geometry and chemistry. Geometry implies the shape complementarity between 
the protein and the ligand. The ligand binds to the protein with a specific 
geometry, where the geometry is defined by the location, the orientation and the 
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conformation of the ligand within the protein binding site. Chemistry implies the 
occurrence of specific and favorable protein-ligand non-covalent interactions 
(Figure 1.9) [51, 52]. In the unbound state, protein and ligand are separately 
solvated and do not interact, whereas in the bound state both partners are 
partially desolvated and form non-covalent interactions between each other. 
 
 
Figure 1.9 A schematic overview of the geometry and chemistry contributions to    
protein-ligand interaction. The protein (P, in violet) and the ligand (L, in green) interact to 
form the protein-ligand complex (PL). Non-covalent interactions are represented as 
dashed lines, where are represented H-bonds in yellow, van der Waals interactions in 
black and electrostatic interactions in orange. 
 
 
The interaction of a protein, P, with a ligand, L, to form a protein-ligand complex, 
PL, can be written as follows: 
 
PLLP   (1.1) 
 
It is common practice to describe the equilibrium represented in equation 1.1 by 
the dissociation constant, dK : 
 
  
 PL
LP
Kd   (1.2) 
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where dK  has the dimensions of a concentration (mol/L) and represents the 
protein-ligand binding affinity. The smaller the dK  value, the more strongly the 
ligand binds to the protein [51, 53]. A non-covalent association of a protein and a 
ligand is governed by general thermodynamics and it occurs only when it is 
characterized by a negative Gibb’s energy, G : 
 
STHG   (1.3) 
 
The enthalpic contribution, H , reflects the strength of the non-covalent 
interactions between the protein and the ligand. The entropic contribution, S , 
relates to changes in the order of both the protein and the ligand in the complex 
formation process and of the solvent. T  is the temperature of the system [51, 54]. 
The relationship between the Gibbs energy and the binding affinity is given by 
equation 1.4: 
 
dKRTG ln  (1.4) 
 
where R  is the gas constant, T  the temperature and dK  the dissociation constant 
previously described [51, 54, 55]. At ‘room temperature’ (T  equal to 298 K and R  
equal to 8.314 J K-1 mol-1) and using 2.303 as conversion factor between natural 
logarithm ( ln ) and logarithm to the base 10 ( 10log ), equation 1.4 becomes: 
 
dKG 10log4.1  (1.5) 
 
This means that each free energy change of 1.4 kcal/mol will lead to a 10 fold 
change in dK .[56]. Generally, biologically important non-covalent interactions 
have dissociation constants that range from picomolar (~1*10-12) for the tightest 
interactions to millimolar (~1*10-3) for the weakest ones. These correspond to free 
energy of binding ranging from ~-17 kcal/mol to ~-4 kcal/mol [53, 55]. The typical          
non-covalent interactions found in protein-ligand complexes are reported in Table 
1.1. 
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Table 1.1 Common protein-ligand interactions with relative enthalpic contributions in 
kcal/mol. 
Interactions Example Energy (kcal/mol) 
van der Waals  Alkyl groups 0.1-1 
Hydrogen bond  X-H ---Ya 2-30 
Electrostatic +--- - b 1-20 
Hydrophobic Non polar groups <10 
a) X is the H-bond donor and Y the H-bond acceptor 
b) It represents an ion-dipole interaction 
 
 
The van der Waals (vdW) interactions are both attractive and repulsive 
interactions. Attractive vdW involve two induced dipoles, atoms or molecules that 
are at a given distance and are not covalently bound. Repulsive vdW interactions 
occur when the two induced dipoles become too close to each other. The vdW 
interactions are described by the Lennard-Jones potential (LJ potential): 
 





















612
4
rr
VLJ

  (1.6) 
 
where   is the depth of the potential,   is the distance at which the interparticle 
potential is zero and r  the distance between the particles. The r -12 term is the 
repulsive short-range term and the r -6 is the attractive long-range term [54, 57]. 
Those interactions are very weak compared to other non-covalent interactions 
(Table 1.1) and to covalent bonds (e.g. the covalent C-C bond has an energy of 
~83 kcal/mol [58]). 
The H-bonds result from an electrostatic interaction between one hydrogen atom 
covalently bound to an electronegative atom called ‘donor’, D, and an 
electronegative atom called ‘acceptor’, A (Figure 1.10). H-bonds are highly 
directional and generate interatomic distances shorter than the sum of the van der 
Waals radii of the involved atoms [54, 55]. Typically, the distance between H-bond 
donors and acceptors ranges from 2.5 to 3.2 Å and the D-H---A angles have 
values between 130° and 180° [59]. In biological systems, such as protein-ligand 
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complexes, H-bonds follow strict geometric rules (their orientations, lengths and 
angles) and that makes those interactions very specific [56]. 
 
 
Figure 1.10. Schematic representation of an H-bond. A is the acceptor, D the donor and 
H the hydrogen atom. d represents the donor-acceptor distance while  is the D-H---A 
angle.  
 
 
Electrostatic interactions are long-range interactions and can be attractive or 
repulsive. They are classified in three types, charge-charge (between charged 
groups), charge-dipole (that normally occur between ionized amino acid side 
chains and the dipole of the ligand or a water molecule) and dipole-dipole. All 
types of electrostatic interactions are described by Coulomb’s law: 
 
12
21
r
qq
kV

  (1.7) 
 
where 1q  and 2q  are the interacting particles,   is the dielectric constant of the 
medium in which particles are placed, 12r  is the distance between 1q  and 2q  and 
k  is the Coulomb’s constant [54, 55]. 
Hydrophobic interactions occur between non-polar ligands and hydrophobic side 
chains protein residues. Generally, the hydrophobic residues and hydrophobic 
ligands repel water molecules resulting in a net non-polar attraction. The    
protein-ligand binding displaces water molecules from the protein interaction 
interface and from the interaction interface of the ligand to the bulk solvent. The 
d 
 
A 
H 
D 
16 
 
release of water molecules to the solvent results in a loss of enthalpy due to the 
disruption of protein-water and ligand-water interactions. The enthalpy loss is 
compensated by a gain of entropy, indeed water molecules are transferred from 
an organized network (around protein and ligand) to the bulk solvent (Figure 1.11) 
[54, 56, 60]. 
 
 
Figure 1.11. Schematic representation of protein-ligand hydrophobic interactions. Orange 
circle represent the protein, black crooked line the ligand and blue circles water 
molecules. 
 
 
1.5 Computational approaches to compute protein-ligand affinity 
 
 
Molecular recognition of proteins with specific ligands is central to biology. It is the 
basis of many processes such as hormonal control or enzymatic catalysis, just to 
cite a few. It is also the foundation for exogenous control of biological systems 
and many medications act by binding specific macromolecular targets. Indeed, the 
experimental identification of a ligand that specifically binds to a target protein is 
of great importance to elucidate the functional role of the protein and is a 
significant step in drug discovery. However, the ligand identification is a major and 
costly challenge. Computational methods can speed up this process and the 
calculated binding affinities can reduce the number of in vitro and in vivo 
experiments to perform [61, 62]. The theoretical treatment of protein-ligand 
binding requires the consideration of all species involved in the binding process 
(protein, ligand, protein-ligand complex, water and counterions) and of all possible 
interactions [51]. Moreover, both protein and ligand are flexible and have many 
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degrees of freedom and thus the exploration of all potential relevant 
conformations is a considerable computational task [61]. To date, there are 
numerous available computational methods that differ in their accuracy, 
complexity and speed. In this work, we focus on scoring functions and free energy 
methods.  
 
 
1.5.1 Scoring functions 
Protein-ligand scoring functions usually take into account only one protein-ligand 
complex structure and do not consider the unbound state of the binding partners. 
They are based on the assumption that the complex conformation used during 
computation is the only one that is significantly occupied. Scoring functions use 
one complex conformation, a simplified energy model and a simplified solvent 
model for the purpose of computational speed. In addition, they are system 
dependent and thus different methods perform better with different systems [61]. 
The most common scoring functions are organized in three main classes: 
knowledge-based, empirical and force field-based scoring functions. 
Knowledge-based scoring functions employ energy potentials that are derived 
from structural information of experimentally determined protein-ligand structures 
(available in databases such as the Protein Data Bank, PDB [63], and the 
Cambridge Structural Database, CSD [64]). The energy of a complex is calculated 
as the combination of energy potential terms for all pairwise contacts. Pairwise 
contacts are converted into energy potential,  iw , by the inverse Boltzman’s law: 
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where bk  is the Boltzman constant, T  is the absolute temperature of the system, 
 i  is a state-dependent density function and ref  is the density function of the 
reference state. Knowledge-based scoring functions offer a good balance 
between accuracy and speed. A disadvantage is that the set of protein-ligand 
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structures needed to derive distance information is limited [65-67]. Examples of 
such scoring functions are DrugScore [68], PMF [69] and SMoG [70].  
Empirical scoring functions estimate the binding affinity of a protein-ligand 
complex by summing up a set of weighted energy terms: 
 
 
i
ii GWG  (1.9) 
 
where iG  represents diverse energy terms (vdW energy, electrostatic energy,  
H-bond energy, hydrophobic terms and etc.) and iW  is a weighted coefficient 
determined by regression analysis. The analysis uses experimental binding affinity 
data of a training set of protein-ligand complexes with a known 3D structure. The 
interesting feature of empirical scoring functions is the simple functional form. This 
implies that the methods are quite fast. On the other hand, the regression analysis 
needed to determine the weighted coefficients depends on the data set used [65-
67]. GlideScore [71], X-Score [72], LUDI [73] and F-Score [74] are some 
examples of empirical scoring functions. 
Force field-based scoring functions are based on the decomposition of the 
protein-ligand binding affinity into individual interaction terms (e.g. vdW 
interactions, electrostatic interactions, bond stretching, bond bending and 
torsional energies). The main feature is that such scoring functions avoid specific 
parameterization using a set of parameters derived by well-established force fields 
[65-67]. One of the most significant limitations of these methods is the exclusion of 
the solvent although recent implementations include models to treat the solvent 
implicitly or explicitly [75]. Examples of force field-based scoring functions are 
GOLD [76], AutoDock [77] and DOCK [78]. 
Each scoring function has its advantages and limitations. To take advantages of 
different scoring functions and to balance errors, consensus scoring functions 
have been introduced. They combine information from different scores [65]. An 
example of a consensus scoring function is X-Score. 
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1.5.2 Free energy methods 
Free energy methods use conformational sampling to generate thermodynamic 
averages. The use of averages is an advantage because it removes sensitivity to 
the details of a single conformation, as is the case in scoring functions. On the 
other hand, the use of conformational sampling requires more computational time 
to generate converged results [61]. It is estimated that to compute the binding 
affinity of a single ligand with a target protein, free energy methods need about 
two days versus one minute with scoring function approaches [62]. 
Conformational sampling can be performed by molecular dynamics (MD) 
simulations. They are generally used to get successive conformations of a given 
system and the ensemble of sequential time-dependent conformations, called a 
MD trajectory, is used to calculate diverse properties of the system of interest. The 
potential energy of a studied system is calculated using a force field that is given 
by a functional form and a set of parameters (that can be derived from 
experimental works or quantum mechanical calculations). Given a force field and 
the initial position of the system of interest, it is possible to perform a MD 
simulation and calculate the trajectory. A commonly used force field is AMBER 
[79, 80] whose functional form is: 
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The equation 1.10 represents the potential energy, V , as function of the system 
structure r . It is separated into the internal terms, including bond, angle and 
torsion contributions, and the nonbonded terms that include vdW and electrostatic 
terms. The parameters 0b  and 0  represent equilibrium bond and angle terms, n  
is the periodicity of the dihedral term and   its phase. The parameters b ,   and 
  are bonds, angles and dihedrals that define the structure r . bK , K  and K  
are bond, angle and dihedral force constants. The nonbonded terms are the vdW 
term described by the Lennard-Jones potential and the electrostatic term 
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described by Coulomb’s law. Another commonly used force field the Optimized 
Potentials for Liquid Simulations, OPLS [81, 82]. Its functional form is based on 
AMBER and the nonbonded interaction parameters have been developed from 
extensive Monte Carlo (MC) simulations of small molecules whereas in AMBER 
they come from experimental data. Thus, OPLS is expected to better describe a 
system were nonbonded interactions are particularly important (such as a protein-
ligand complex) [83]. 
Free energy methods are organized into two classes, ‘alchemical’ methods and 
‘end-point’ methods.  
‘Alchemical’ methods employ unphysical (‘alchemical’) transformations to estimate 
the free energies of several physical processes such as protein-ligand binding. In 
the case of a ligand that binds to a protein, the alchemical transformation is the 
conversion of a ligand into another, unphysical ligand, within the binding site and 
in solution [61]. Free energy perturbation (FEP) and thermodynamic integration 
(TI) are two ‘alchemical’ free energy methods that use a thermodynamic cycle like 
that one represented in Figure 1.12.  
 
 
 
Figure 1.12. Schematic representation of the thermodynamic cycle used by FEP and TI 
methods, from [62]. P is the protein, X and Y are ligands. The GX and GY are the 
change in free energy for the formation of the complexes PX and PY, respectively. GF 
and GC are the change in free energy for the transformation of ligand X into Y in solution 
and within the protein binding site, respectively. 
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The thermodynamic cycle in Figure 1.12 can be written as: 
 
0 FYYX GGGG  (1.11) 
 
YG  is the change in free energy when the unphysical ligand Y binds to the 
protein. Since an unphysical ligand is not able to interact with the solvent or the 
protein, this quantity is always equal to zero. Equation 1.11 becomes: 
 
CFX GGG   (1.12) 
 
Therefore, the free energy of binding of the ligand X to the protein P is given by 
the difference of the change in free energy for the transformation of the ligand X 
into the ligand Y in solution and within the binding site of the protein P. 
FEP and TI employ long MD or MC simulations and an explicit treatment of the 
solvent. They are time consuming methods that give a good estimation of binding 
energy, with errors of about 1 to 2 kcal/mol [61]. A limitation of such methods is 
that the alchemical transformation cannot be too drastic. This restricts the diversity 
of the ligands that can be treated and also the possibility of examining the effect of 
significant protein mutations on the binding of given ligands since usually protein 
mutations are considered large perturbations [84]. 
‘End-point’ methods compute the change in free energy only considering the initial 
and finale states of a given process [61]. A first ‘end-point’ method is the linear 
interaction energy (LIE) method. In the case of protein-ligand binding it involves 
running two MD simulations, one for the ligand in solution and another for the 
ligand within the protein binding site [85]. An ensemble of conformations obtained 
for the initial and the final states is used to compute the average electrostatic 
( elecE ) and average vdW ( vdWE ) interaction energies of the ligand within its 
environment in the initial state, the free state, and in the bound state. The free 
energy of binding is estimated as follows: 
 
   
freevdWboundvdWfreeelecboundelecbind
EEEEG    (1.13) 
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where the angle brackets indicate the averages for the interaction energy terms. 
The factor   and   accounts for changes in the internal energy of the solvent 
and the protein in response to the interaction with the ligand and they are 
determined empirically [85]. A drawback of LIE is that it is not really universal 
since   and   are system dependent. They have to be determined for each case 
of study and requires available experimental data [84]. A second ‘end-point’ 
method is the molecular mechanics-Poisson Boltzmann surface area (MM-PBSA) 
method together with its generalized Born (GB) variant (MM-GBSA). Generally, 
those methods use MD simulations of the free protein, the free ligand and their 
complex (three-trajectory approach) to obtain conformation ensembles that, in 
turn, are used to compute the average energy terms that contribute to the free 
energy of binding [60, 61]. The solvent is treated implicitly using either PBSA [86] 
or GBSA [87] models. The nonpolar contribution is assumed to be proportional to 
the solvent accessible surface area (SASA) and the electrostatic contribution is 
given by the continuum-electrostatics models PB or GB (that is an approximation 
of the exact PB equation). Figure 1.13 shows the thermodynamics cycle used in 
MM-PBSA and MM-GBSA methods. 
The free energy of binding is given by the following formula: 
 
 solvligsolvprotsolvcompsolvbind GGGG ,,,,   (1.13). 
 
The MD simulation can also be performed using a protocol known as            
single-trajectory approach. In that case, a MD simulation is performed only for the 
protein-ligand complex and results converge faster than using the three-trajectory 
approach [61]. 
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Figure 1.13. Schematic representation of the thermodynamic cycle used for MM-PBSA 
and MM-GBSA calculations. Ggas and Gbind,solv are the free energy of binding for the 
formation of the complex in vacuum and in solution. Gprot,sol, Glig,solv and Gcomp,solv are 
Gs for the transition of the protein, the ligand and complex from gas to the solvent.  
 
 
1.6 Mycobacterium tuberculosis protein kinase G, an attractive 
target 
 
We applied the computational protocol developed in this work to a specific kinase, 
the Mycobacterium tuberculosis (Mtb) serine/threonine protein kinase G (PknG). 
Mtb is a pathogenic bacterium and is the causative agent of tuberculosis (TB). TB 
is a widespread infectious disease and causes around two million deaths per year 
[88]. It generally affects the lungs and is spread through the air when infected 
people cough or sneeze [89]. Nowadays there is a global increase in              
drug-resistant TB cases and therefore there is an urgent need to develop new 
therapies to combat this infectious disease [90]. 
Mtb belongs to the family of Mycobacteriaceae. The virulence of Mtb is related to 
its capacity to survive within the host alveolar macrophage. In general the first 
barrier pathogens come across when infecting a multicellular organism is the 
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immune defense system. A key cell of the immune system is the macrophage that 
is a phagocyte which recognizes microbes and engulfs them into vacuoles called 
phagosomes. Phagosomes then fuse with lysosomes, called phagolysosome 
biogenesis, resulting in the degradation of pathogens (Figure 1.14, right side). In 
the case of Mtb, the mycobacteria are picked-up by macrophage but they survive 
and replicate intracellularly causing the infection. Diverse studies have shown 
that, upon Mtb infection, the secretion of PknG within the macrophage cytosol 
prevent the phagolysosome biogenesis promoting the survival of the parasite 
within the host organism [91, 92] (Figure 1.14, left side).  
 
 
Figure 1.14. ( From [93]) Immune system response upon pathogenic mycobacteria 
infection. Blue mycobacteria (on the right side) represent generic pathogens, green 
mycobacteria (on the left side) represent Mtb.  
 
 
Mtb genome includes genes encoding 11 serine/threonine protein kinases, PknA, 
PknB, PknD, PknE, PknF, PknG, PknH, PknI, PknJ, PknK and PknL. Except for 
PknG and PknK, which are soluble proteins, all other serine/threonine kinases are 
transmembrane proteins [94, 95]. Inactivation of PknG gene resulted in decreased 
viability of Mtb both in vitro and in vivo (mice) [96], and the blocking of PknG 
kinase activity by tetrahydrobenzothophene (AXX) results in bacterium 
degradation [97]. Although experimental evidence supports the significant role of  
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PknG in mycobacterium survival, its downstream substrates involved in pathway 
mediating infectivity and its precise mode of action remain unknown.  
The PknG kinase domain has the classical bilobal fold, with the ATP binding site 
located within the cleft between the N-lobe and the C-lobe. The kinase domain is 
sandwiched between the rubredoxin (Rdx) domain, probably involved in PknG 
activity regulation, and a tetratricopeptide repeat (TPR) domain, probably involved 
in mediating protein-protein interactions [97] (Figure 1.15).  
 
 
Figure 1.15. Surface representation of PknG (PDB: 2PZI). The kinase domain is 
sandwiched between the Rdx and the TPR domains. AXX occupies the ATP binding cleft. 
 
 
To date, it is known that GarA is a physiological substrate of PknG in Mtb [98]. 
GarA is a forkhead associated (FHA) protein of 162 residues. The FHA domain 
folds into an 11-stranded  sandwich [99] and is preceded by an N-terminal 
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peptide extension of about 50 residues (Figure 1.16). The N-terminal peptide 
contains a highly conserved ETTS motif which, in turn, contains the residue 
phosphorylated by PknG, Thr21 (Figure 1.16). GarA controls glycogen 
degradation and glutamate metabolism [100, 101].  
 
 
Figure 1.6 Schematic representation of GarA. The motif ETTS contains the 
phosphorylation site, Thr21 (red). 
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1.7 Objectives 
 
This work aims to develop a computational protocol for the engineering of protein 
kinases. We intend to predict which residues within the binding pocket of the 
target kinase could be mutated to change its co-substrate specificity from ATP to 
an ATP analogue. The protocol explores pairings of potential mutations and ATP 
analogues and might be part of a wider experiment for identifying specific 
substrates of protein kinases and better understanding role of these enzymes in 
cell pathways.  
We validated the computational protocol on different tyrosine and serine/threonine 
protein kinases from the scientific literature where Shokat’s method was applied 
and experimental data were available. Subsequently, we applied our protocol to 
the Mycobacterium tuberculosis protein kinase G, PknG. PknG plays a key role in 
the survival of M.tuberculosis within the host organism and its specific 
downstream substrates as well as its mechanism of action are unknown. The in 
silico protocol allowed us to design a number of pairs of PknG mutants and ATP 
analogues and the designed pairs were tested in vitro. 
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2 Methods 
 
This chapter describes the method developed and used in this thesis. Figure 2.1 
shows a schematic representation of the computational protocol that is organized 
in two main parts. The first part is an algorithm to predict residues to mutate within 
the ligand-binding site of a kinase of interest to generate an engineered kinase. 
The second part consists in the evaluation of the interaction between an 
engineered kinase and a ligand analogue.  
 
 
Figure 2.1. Workflow of the computational protocol. The entire protocol is organized in 
two parts, the first part identifies residues to mutate and the 2nd part evaluates mutant-
analogue interactions. The specific inputs are depicted in circles, steps of the workflow 
are shown in rectangles and outputs are depicted in rectangles with dashed lines. In case 
no residues are identified for the in silico mutagenesis, the analogue is assumed to act as 
substrate for the wild-type protein and thus is discarded (red arrow).  
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The protocol was tested on a literature-based test set containing 7 wild-type 
kinase proteins and 15 kinase mutants to which the Shokat’s method was applied 
and for which experimental data were available. Afterwards, the protocol was 
applied to the Mycobacterium tuberculosis protein kinase G. 
 
 
2.1 Input structures 
 
We collect the kinase structures as well as structures of natural ligands to use as 
input structures. The kinases structures are X-ray structures from the Protein Data 
Bank (PDB, [63]) and natural ligands come from known PDB structures. Table 2.1 
shows wild-type kinases, PDB entries, engineered kinases and natural ligands 
used in this work. 
 
Table 1.1. Kinase proteins, kinase mutants, natural ligands and PDB entries used in our 
work. 
Kinases PDB  Kinase mutants Natural ligands 
v-Src [18] 2SRC* v-SrcI338A 
v-SrcI338G 
ANP 
 
JNK [27] 1JNK JNKM108GL168A ANP 
v-Src [102] 
 
2SRC* v-SrcI338A 
v-SrcI338G 
v-SrcI338F 
v-SrcI338M 
v-SrcI338S 
v-SrcI338T 
v-SrcI338V 
v-SrcI338C 
PP1 pyrazolepirimidine core  
Fyn 2DQ7 FynT338A  
Abl 2G1T AblT334A  
CamKII 2VZ6 CamKIIF89G  
Cdk2 1HCK Cdk2F80G  
P38 1DI9 P38T106A 
P38T106G 
 
PknG 2PZI PknGM232G, PknGV211G 
PknGM232H, PknGM232S 
PknGM232T, PknGV235G 
PknGY234G 
ATP 
*A model for v-Src was built based on the structure of c-Src whose PDB is 2SRC. 
30 
 
Unless stated otherwise, in silico mutagenesis was performed using Maestro 
(version 9.5, Schrödinger, LLC, New York, NY, 2013) and structures were 
prepared with the Protein Preparation Wizard tool [103]. Residues are numbered 
as in PDB structures. 
To date, the crystal structure of the cellular proto-oncogene tyrosine-protein 
kinase Src (c-Src) in complex with ANP (an ATP analogue with an amino group in 
place of the oxygen between  and  phosphates) has been solved (Homo 
sapiens, PDB: 2SRC, resolution 1.50 Å [45]). The kinase domain of the viral  
proto-oncogene tyrosine-protein kinase Src (v-Src) differs from that of c-Src at the 
position 338 within the ligand-binding pocket. It is an Ile (Ile338) in v-Src and a Thr 
(Thr338) in c-Src. The rest of the sequences are identical. To obtain the model of 
v-Src bound to ANP, we mutated in silico Thr338 of c-Src into Ile. The model of   
v-Src in complex with ANP was then prepared as follows: first, we added 
hydrogen atoms that are generally not visible in X-ray structures [104]. Then, we 
optimized the hydrogen bonding network and the orientation of the amide groups 
of Asn, Gln and of the imidazole ring of His. This optimization allowed for 
improved interactions between charged groups as well as hydrogen bonds within 
the structure. The optimization was performed at pH 7.0. Finally, a minimization 
step allowed the model to relax. The Optimized Potentials for Liquid Simulations 
(OPLS_2005) [81, 82] was used as force field and the termination criterion was 
based on the root mean square deviation (rmsd) of the heavy atoms relative to 
their initial location (rmsd ≤ 0.30 Å). The v-SrcI338A and v-SrcI338G mutants 
were obtained in the same way. 
The crystal structure of JNK bound to ANP and Mg2+ was solved in 1998 (Homo 
sapiens, PDB: 1JNK, resolution 2.30 Å [105]). The M108GL168A mutant in 
complex with ANP was obtained by mutating in silico Met108 to Gly and Leu168 
to Ala. The structure of wild-type JNK in complex with ANP and the model of the 
engineered JNK in complex with ANP were prepared as described above. 
The pyrazolopyrimidine core of PP1 (1-tert-butyl-3-(4-methylphenyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine) mimics the adenine ring of ATP in its binding 
within the nucleotide-binding pocket of a kinase protein (Figure 2.2). To obtain a 
model of v-Src in complex with the pyrazolopyrimidine core of PP1, we proceeded 
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in the following way. The model of v-Src bound to ANP was superposed onto the 
structure of the hematopoietic cell kinase Hck, a homologous protein, in complex 
with PP1 (Homo sapiens, PDB: 1QCF, resolution 2.00 Å [106]). The superposition 
was performed using residues belonging to the hinge regions (residues 338 to 
341 in both v-Src and Hck) and the coordinates of the PP1 core were copied into 
the v-Src binding pocket. The same procedure was used for the other protein 
kinases, proto-oncogene c-Fyn (Fyn, Homo sapiens, PDB: 2DQ7, resolution 2.80 
Å [107]), Abelson murine leukemia viral oncogene homolog 1 (Abl, Homo sapiens, 
PDB: 2G1T, chain D, resolution 1.80 Å [108]), Calcium/calmodulin-dependent 
protein kinase type II subunit alpha (CamKII, Homo sapiens, PDB: 2VZ6, chain B, 
resolution 2.30 Å [109]), Cyclin-dependent kinase 2 (Cdk2, Homo sapiens, PDB: 
1HCK, resolution 1.90 Å [110]), and Mitogen-activated protein kinase p38 alpha 
(P38, Homo sapiens, PDB: 1DI9, resolution 2.60 Å [111]). 
The structure of the Mycobacterium tuberculosis protein kinase G, Mtb PknG, 
bound to AXX (2-[(cyclopropylcarbonyl)amino]-4,5,6,7-tetrahydro-1-
benzothiophene-3-carboxamide) had been solved (PDB: 2PZI, resolution 2.40 Å 
[97]). The kinase domain of the PknG structure (residue 151 to 396) contained 2 
gaps, 1 residue missing between amino acid 304 and 306 and 4 residues missing 
in the C-lobe between position 241 and 246. To build the missing parts, we built a 
homology model of PknG using Modeller 9.10 [112]. Two proteins were used as 
templates, PknG itself and the homologous serine/threonine protein kinase B 
(PknB) from the same organism (28.40% sequence identity, PDB: 3ORO, 
resolution 1.90 Å [113]). The second structure was used as template for the 
missing parts of PknG. The obtained model and the crystal structure of PknG 
were superposed using backbone atoms (rmsd 0.017 Å) and the gaps within the 
crystal structure were replaced by the corresponding parts in the model. The 
quality of the model of PknG was estimated by the QMEAN scoring function (good 
model with a QMEAN score = 0.727, [114]). Once the structure of PknG was 
fixed, it was superposed onto the structure of PknB in complex with AGS (an ATP 
analogue with a sulfur atom bound to  phosphate). Superposition was made 
using hinge regions and the AGS coordinates were copied within the PknG  
ligand-binding site. All PknG mutants were prepared as described before.  
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Ligand analogues used in this study (N6-(benzyl) ATP, N6-(2-phenythyl) ATP,  
N6-(cyclopentyl) ATP, N6-(1-methylbutyl) ATP, PP1, N6-(methyl) ATP, 8-Azido 
ATP, 2-(phenylethynyl) ATP (PF9) and 7-deaza-7propargylamino-ATP (7d7p 
ATP)) are created in the Maestro graphical interface and are represented in 
Figure 2.2.  
 
 
Figure 2.2. Chemical structures of ATP analogues used in this work. For simplicity, only 
the adenine base is represented. 
 
 
For each molecule, an ensemble of low energy conformers was generated by 
performing an in vacuum conformational search keeping the adenine base, the 
ribose ring, the phosphates and the pyrazolopyrimidine core of PP1 fixed and 
allowing the bonds of each substituent group to rotate freely. We used the Monte 
Carlo multiple minimum (MCMM) method [115] for 10 000 steps, the OPLS_2005 
force field, and a threshold value of 100 Kj/mol. During the conformational search, 
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new structures generated were retained if they exhibited conformational energies 
lower than 100 kJ/mol. Moreover, to obtain an ensemble of unique structures and 
eliminate redundant conformers, each conformer was compared with the previous 
ones and only retained if the root mean square deviation (rmsd) for all atoms 
exceeds 0.5 Å. The conformational search was performed with the MacroModel 
module implemented in the Schrödinger suite (version 10.1, Schrödinger, LLC, 
New York, NY, 2013). 
 
 
2.2 Computational protocol 
 
The first part of the protocol (Figure 2.1) was written in Python 2.5.4 and 
contained functions from the OpenStructure software framework [116]. The 
structures of target kinases and the natural ligands were used to define the  
ligand-binding site. The pocket was defined by all residues within 5 Å from the 
atom position on the natural ligand at which the substituent group was attached. 
For example, if the natural ligand was ATP and the ligand analogue was           
N6-(methyl) ATP, the N6 ATP atom defined the binding pocket of the target 
protein kinase. For each analogue, the ensemble was superposed onto the 
adenine moiety of the native ligand within the binding pocket of the reference 
protein. The identification of residues to mutate was based on a distance criterion. 
If the distance between an atom of a protein residue and any atom of the 
substituent group of a ligand analogue is shorter than the sum of their van der 
Waals (vdW) radii, the corresponding residue is a potential candidate for 
mutagenesis. The vdW radii for each atom come from the Cambridge Structural 
Database, CSD [64] (Appendix A.1). If no residues were identified for point 
mutations it means that the analogue could potentially act as substrate for the 
native target and not only for the engineered protein and is thus discarded. 
One of the most important contributions to the stabilization of protein-ligand 
complexes is given by hydrogen bonds (H-bonds). In case of non-halogenated 
ligands, two atoms are generally involved in protein-ligand H-bonds, nitrogen (N) 
and oxygen (O). When N and O are involved in H-bonds, the distance between 
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them is smaller than the sum of their vdW radii. For instance, if N acts as 
hydrogen donor the N-O distance becomes 3.04 Å instead of 3.07 Å (sum of their 
vdW radii) and if O acts as H-bond donor the O-O distance becomes 2.70 Å 
instead of 3.04 Å and O-N becomes 2.88 Å instead of 3.07 Å [30, 117]. To take 
into account the distances between atoms that could be involved in H-bonds, we 
introduced a tolerance value. The tolerance value was calculated as the 
difference between the sum of the vdW radii of two atoms and their distance in 
case they are involved in H-bonds. For example, in case of the O-O distance the 
tolerance value is given by 3.04 Å (sum of vdW radii) minus 2.70 Å (donor-
acceptor distance in case of H-bond). The tolerance values were computed for all 
atom pairs that can be involved in protein-ligand H-bonds and a value of 0.5 Å 
was chosen as general tolerance value (since it included all possible calculated 
values). The distance criterion was thus given by the formula: 
 
tvsumvdWd   (2.1) 
 
If the distance d  between a protein-ligand atom pair is smaller than the sum of 
their vdW radii minus the tolerance value, tv , the corresponding residue is a 
potential candidate for mutagenesis. 
In the second part of the computational protocol, residues identified as possible 
candidates for mutagenesis were mutated in silico to generate kinase mutants 
(Table 2.1). The kinase mutant-ligand conformer pairs were evaluated and ranked 
by the empirical protein-ligand scoring function GlideScore as implemented in the 
Scrödinger suite [71] (Figure 2.1). GlideScore is given by equation 2.2: 
 
BuryPvdWCoulSiteRotBMetalHbondLipoGScore   (2.2) 
Lipo  is the lipophilic term and rewards favorable receptor-ligand hydrophobic 
interactions. It is a function of the receptor-atomligand-atom distances: 
 
  lrlipo rfCLipo  (2.3) 
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Hbond  represents the hydrogen bonds term. It is separated into three weighted 
components that depend on whether the donor and the acceptor are both neutral, 
one neutral and one charged, or both charged. It depends on hydrogen bonding 
distances and angles: 
 
     hrgCHbond hbond  (2.4) 
 
where r  is the distance between the donor and acceptor and   is the          
donor-acceptor angle. Metal  is the metal term and describes the interaction 
between ligand atoms and metal ions eventually present in the receptor: 
 
  lrmetal rfCMetal  (2.5) 
 
RotB  is a penalty term for frozen rotable bonds. Bonds are considered frozen if 
atoms on both sides of a rotable bond of the ligand (any sp3-sp3 and any sp2-sp3 
bond) are in contact with receptor. Site  is a term that accounts for polar 
interactions. It rewards for polar group found in hydrophilic regions. Coul  and 
vdW  account for Coulomb energy and van der Waals energy, respectively. Coul  
is described by the Coulomb’s law and vdW  by the Lennard-Jones potential 
(equations 2.6 and 2.7). 
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The quantities lq  and rq  are the charges of ligand atoms and receptor atoms, k  
is the Coulomb’s constant, 0,lrr  is the ligand-receptor distance at which the 
potential reaches its minimum and lrr  is the ligand-receptor distance. Both terms 
are computed with reduced net ionic charges on groups with formal charges (such 
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as acetate or guanidinium) to avoid an over reward of charge-charge interactions 
with respect to charge-dipole and dipole-dipole interactions. Finally, BuryP  is a 
penalty term for buried polar groups. 
All terms in equation 2.2 are multiplied by coefficients determined by reproducing 
binding affinities of a training set of protein-ligand complexes with known       
three-dimensional structures. The Lipo  and vdW  terms account for nearly 80% of 
the total score. The most promising pair of kinase mutant and analogue conformer 
was the one with the best GlideScore, and for this the Glide Energy was taken 
into account. The Glide energy is the sum of the Coul  and the vdW  terms and 
represents a protein-ligand interaction energy. The correlation between 
experimental IC50 values and predicting energies of interaction (Glide energies) 
shows that the Glide energy is more suitable to describe and compare        
protein-ligand binding affinities [118].  
For all pairs of kinase mutants and ATP analogues, to be independent from the 
various ribose ring and phosphates conformations, position and orientations within 
the binding site (see Introduction, paragraph 1.3), only the adenine base and the 
substituent group were scored by GlideScore and not the rest of the molecule 
(Appendix A.2). 
 
 
2.3 Methods to score protein-ligand interactions 
 
Besides GlideScore, we evaluated other two protein-ligand scoring functions,      
X-Score [72] and DrugScore eXtended (DSX, [68]). We also tested the Molecular 
Mechanics-Generalized Born Surface Area, MM-GBSA, method [119]). We 
checked the ability of the scoring functions and the free energy method to 
reproduce experimental data available for v-Src and an ATP derivative. 
 
 
2.3.1 X-Score 
X-Score is an empirical consensus protein-ligand scoring function. It is the 
arithmetical average of three empirical scoring functions: 
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  3/HSScoreHMScoreHCScoreScoreX   (2.8) 
 
All terms in equation 2.8 are calculated summing up five terms that account for 
protein-ligand interactions: 
 
HCRTHBVDWHCScore   (2.9) 
 
HMRTHBVDWHMScore   (2.10) 
 
HSRTHBVDWHSScore   (2.11) 
 
All quantities in these three scoring functions are calculated using identical 
algorithms except for the hydrophobic effect terms ( HC , HM  and HS ) that are 
calculated by three different algorithms. Each term in equations 2.9-2.11 is 
multiplied by a coefficient determined by fitting experimental binding affinities of a 
dataset of protein-ligand complexes. VDW  denotes the van der Waals interaction 
energy and it is described by a ‘softer’ Lennard-Jones potential, an 8-4 equation 
instead of the standard 12-6 equation: 
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The term ijd  denotes the distance between the ligand atom i and the protein atom 
j and 0,ijd  is the sum of the vdW radii of atom i and j. HB  accounts for hydrogen 
bonding interaction between the ligand and the protein and it is calculated by 
summing up all hydrogen bonds: 
 
      
ligand
i
protein
j
ijijij ffdfHB ,2,1 **   (2.13) 
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The distance function  ijdf  and the angular functions  ijf ,1  and  ijf ,2  are the 
geometric descriptors of each ligand-protein hydrogen bond. ijd  is the distance 
between the donor (D) and the acceptor (A), ij,1  is the donor angle and ij,2  is the 
acceptor angle. RT  represents the deformation effect, that is the loss of entropy 
when the ligand and the protein are in a bound state with respect to their free 
states in the solvent. The deformation effect of the ligand is estimated by 
considering all rotable bonds ( RT ) that became frozen after the binding whereas 
the deformation effect of the protein is neglected: 
 

ligand
i
iRTRT  (2.14) 
 
Finally, as previously mentioned, the hydrophobic effect is represented by three 
different algorithms. HC  stands for hydrophobic contact algorithm, and this effect 
is calculated by summing up the hydrophobic atom pairs between the ligand and 
the protein: 
 
  
ligand
i
protein
j
ijdfHC  (2.15) 
 
HM  stands for hydrophobic matching algorithm. This term describes as favorable 
to the binding process each hydrophobic ligand atom placed within a hydrophobic 
place of the protein: 
 

ligand
i
iHMHM  (2.16) 
 
iHM  is equal to 1 when a hydrophobic atom is placed in a hydrophobic 
environment and is equal to 0 when it is placed in a hydrophilic environment.  
HS  stands for hydrophobic surface algorithm. The hydrophobic effect is assumed 
to be proportional to the solvent-accessible surface (SAS) area of the ligand: 
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
ligand
i
iSASHS  (2.17) 
 
 
2.3.2 DrugScore eXtended 
The knowledge-based scoring function DrugScore eXtended (DSX) consists of 
distance-dependent pair potentials, torsional potentials and solvent accessible 
surface-dependent potentials. It is given by the equation 2.18: 
 
SRtorspairtotal scorescorescorescore   (2.18) 
 
Each term score  is the classical equation for knowledge-based scoring functions: 
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where  i  is a state-dependent density function and ref  is the density function 
of the reference state. The term pairscore  represents the distance-dependent pair 
potential and is a function of the distance between a protein atom and a ligand 
atom. The knowledge-bases used to derive the DSX pair potential are the PDB 
and CSD. In the PDB, only structures with a resolution less than 2.4 Å and 
containing at least one ligand are taken into account. Moreover, only contacts 
between atoms with B-factors ≤ 40 Å and occupancies ≥ 0.5 were considered. In 
the CSD, only structures with R-factors ≤ 0.075 are considered. The term torsscore  
is the DSX torsional potential. It is a function of the four atoms being part of the 
torsion and of the torsion angle. This term aims to penalize unlikely torsion angles. 
In that case, the knowledge-base is the CSD already used for pairscore . Finally, 
the term SRscore  accounts for the desolvation effect that is based on the solvent-
accessible surface (SAS). It is a function of the SAS ratio, represented by the 
ration of SAS for an atom in complexed state over SAS for an atom in 
uncomplexed state. The PDB is used as the knowledge-base. 
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2.3.3 MM-GBSA method 
The MM-GBSA approach allows for computing the free energy of binding of 
protein-ligand complexes. It requires, at least, one trajectory for the complex of 
interest that is produced by a molecular dynamics (MD) simulation. The MD 
simulations were performed using AMBER 12 [120] and the AMBER ff99SB       
all-atom force field [79, 80]. The starting coordinates for MD simulations were the 
coordinates of the protein-ligand complexes previously described. The ligands 
were automatically parameterized using Antechamber [121]. Each protein-ligand 
complex had a negative charge that was neutralized by adding the proper number 
of sodium ions. Each of the neutralized protein-ligand complexes was solvated 
with a rectangular box of TIP3P water molecules. 
Prior to running the production MD, we performed minimization, heating, and 
equilibration steps described as follows. First of all, water molecules and ions 
were minimized with the steepest descent method (SD) for 2500 steps keeping 
the protein-ligand complex fixed (partial minimization) and then the entire system 
was minimized for other 1000 steps (full minimization). In both partial and full 
minimizations, periodic boundaries based on the Partial Mesh Ewald (PME) [122] 
method were used for calculation of non-bonded interactions, with a cutoff of 9 Å. 
Afterwards, the system was heated from 0 K to 300 K for 50 ps keeping the 
protein-ligand complex fixed and using the NVT ensemble. All bonds involving 
hydrogens were constrained using the SHAKE algorithm [123]. Finally, the system 
was equilibrated for 500 ps switching from the constant volume of the heating step 
to a constant pressure (NPT ensemble). This allowed the solvent to equilibrate 
around the protein-ligand complex. After the minimization, heating, and 
equilibration steps had completed, a long MD simulation was carried out using 
NVT ensemble at a temperature of 300 K for 20 ns with a time step of 2 fs. 
The free energy of binding was calculated using the MM-GBSA approach [124]. 
The binding free energy is calculated by subtracting the free energy of the 
unbound protein and ligand from the free energy of the protein-ligand complex 
(equation 2.20): 
 
 solvatedligandsolvatedproteinsolvatedcomplexsolvatedbound GGGG ,,,,   (2.20) 
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Each term of the right-hand side of equation 2.20 is estimated as follows: 
 
STGEG solvationgassolvated   (2.21) 
 
The brackets indicate averages of each term ( gasE , solvationG  and S ) calculated 
from an ensemble of representative complex structures obtained from the MD 
trajectory.  
The gas-phase energy ( gasE ) is the molecular mechanical (MM) energy from the 
force field. It comprises internal energy terms (bond, angle and torsion energies) 
and the van der Waals and the electrostatic interaction energies between the 
protein and the ligand. Here, we used the single trajectory protocol (STP) 
approach that means we only used the trajectory of the protein-ligand complex to 
generate three ensembles of representative frames, one for the unbound ligand, 
one for the unbound protein and one for the complex [125]. A STP approach does 
not produce any difference between the internal energy terms of the complex and 
the unbound protein and ligand. Thus, those terms cancel out.  
The solvation free energy ( solvationG ) is divided into electrostatic and nonpolar 
contributions. The electrostatic contribution is given by a continuum (implicit) 
solvent model and here we used the generalized Born (GB) model [126, 127]. The 
use of the GB model allows for an increase in the calculation speed compared to 
numerically solving the Poisson equation when the electrostatic contribution is 
estimated by the Poisson-Boltzman approach [128]. The nonpolar contribution is 
proportional to the solvent accessible surface area (SASA) [129]. 
The entropic contribution ( ST ) is given by three terms, the translational, the 
rotational, and the vibrational entropies. The entropic contribution is required to 
calculate absolute free energies of binding. In case of related systems, such as 
two ligands binding to the same protein or vice versa, it is assumed that the solute 
entropy is the same for each system and thus the entropy contribution can be 
neglected. That approximation was applied in our case, allowing the computation 
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of the relative binding free energies [130]. Thus, in this work the equation 2.21 
became: 
 
nonpolarsolvationelecsolvationticelectrostavdwsolvated GGEEG ,,   (2.22) 
 
In that case, frames from the long MD simulation (20 ns) were extracted every 10 
ps resulting in 2000 frames used to apply the MM-GBSA method already 
described. We used the program MMPBSA.py [119]. 
 
 
2.4 Data comparison 
 
All plots reported in this work were made using the Matplotlib and NumPy 
packages [131] [132]. 
The plots of v-Src, v-SrcI338A and v-SrcI338G in complex with ATP and           
N6-(benzyl) ATP were created by comparing the experimental catalytic efficiency 
(kcat/Km) and the predicted interaction energies (Glide energies). To compare 
experimental kcat/Km with computed interaction energies, we calculated the 
logarithm to base 10 (log) of the kcat/Km ratio, in order to use the corresponding 
small integer values, and multiplied the predicted interaction energies by -1, to 
obtain positive values.  
For the engineered JNK (JNKM108GL168A) and the N6-(substituent) ATPs, we 
compared the observed percentage of phosphorylation with the computed 
interaction energies. The predicted quantities were scaled between 0 and 100 to 
fit the same range of observed values. Predicted data were transformed using the 
Min-Max normalization: 
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where,  AA max,min  is the initial range,  AA newnew max_,min_  is the new range 
and v  is the value to transform. The lowest Glide energy was set to 0 and the 
highest to 100.  
The plots of Src tyrosine kinases and serine/threonine kinases in complex with 
PP1 were made measuring the linear correlation between the predicted 
interaction energies and the experimental measured pIC50 (-log(IC50)). For each 
family, the Pearson correlation coefficient was computed. 
 
 
2.5 Experimental methods 
 
We applied our computational protocol for protein engineering to Mtb PknG and 
five purchasable ATP analogues. The predictions made were experimentally 
tested. The experiments were performed using PknG and diverse PknG mutants 
as target proteins, GarA as substrate and three purchasable ATP-competitive 
ligands that were identified as good candidates as cofactors for PknG mutants 
(N6-(benzyl) ATP, PF9 and 7d7p ATP). 
All experiments were performed by Mohamed-Ali Mahii. 
 
 
2.5.1 Proteins expression  
In all experiments the PknGN mutant was used instead of the full length protein. 
PknGN lacks the first 73 residues (N-terminus) and was highly soluble and 
stable compared to the full length protein [97]. 
For expression of His-tagged PknGN, the expression vector pET15b-PknGN 
was transformed in competent Escherichia coli cells (E. coli BL21(DE3)). A pET 
expression vector essentially contains an isopropyl β-D-1-thiogalactopyranoside 
(IPTG) inducible promoter, a ribosome binding site (RBS), the polilinker where the 
foreign gene is inserted, a termination site and a gene for ampicillin resistance. 
The E. coli cells were recovered in Lysogeny Broth (LB) medium, a nutrient-rich 
                                                          
i Mohamed-Ali Mahi, Biozentrum University of Basel, Switzerland 
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medium for allowing rapid and robust growth of bacteria, and then were spread on 
LB-ampicillin (LB-Amp) plates. Each LB-ampicillin plate contained the LB medium 
and the antibiotic ampicillin. Consequently, only cells that were successfully 
transformed and thus contained the expression vector with the gene for ampicillin 
resistance survived in LB-Amp. Once the OD600 indicated that the bacterial 
cultures were in the exponential growth phase (increased bacterial cell 
concentration), the PknGN expression was induced by IPTG.  
The same procedure was used for each PknGN variant and the substrate GarA 
(Table 2.2). 
 
Table 2.2. PknGN variants and expression vectors used. 
PknGN variants Expression vectors 
PknGN-M232G pET15b-PknGN-M232G 
PknGN-V235G pET15b-PknGN-V235G 
PknGN-M232S pET15b-PknGN-M232S 
PknGN-M232T pET15b-PknGN-M232T 
GarA pET15b-GarA 
 
 
2.5.2 Protein purification  
The bacterial pellet, containing the His-tagged PknGN, was suspended in a 
suitable buffer, blended by a homogenizer and the lysate was cleared by 
subsequent centrifugation steps. The supernatant was filtered and applied to a 
HisTrap column to perform an immobilized metal affinity chromatography to purify 
the protein of interest (His-tagged PknGN). The His-tag protein was eluted from 
the column with an elution buffer containing imidazole. The collected fractions 
were tested by SDS-PAGE. The gel was stained with ‘Instant Blue-like’ solutions. 
Fractions contained high amount of His-tagged PknGN were further purified by 
size exclusion chromatography to remove imidazole and to obtain pure protein. 
Collected fractions containing pure protein were again tested by SDS-PAGE. 
Protein concentration was determined by direct UV Absorbance at 280 nm (UV 
A280nm).  
The same protocol was used to purify PknGN mutants and the substrate GarA. 
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2.5.3 Kinase assays 
The kinase activity of PknGN and PknGN mutants was checked by performing 
in vitro kinase assays. PknGN and PknGN mutants did not have 
autophosphorylation activity since the cluster of autophosphorylation sites (Thr23, 
Thr32, Thr63 and Thr64) was located in the removed N-terminus [133]. This 
deletion allows avoiding kinase autophosphorylation signals on the gel. The 
deletion of the N-terminus did not affect the kinase activity of PknG [97].The in 
vitro phosphorylation was carried out preparing two reaction mixes for each 
protein kinase. Each reaction mix contained the protein kinase of interest 
(PknGN or a PknGN mutant), the substrate GarA, the natural ATP or an ATP 
analogue and MnCl2. The presence of manganese chloride was necessary 
because divalent cations (in that case Mn2+) are required from kinase proteins to 
be active and to phosphorylate a specific substrate. Reactions were quenched by 
adding EDTA to the reaction mix. Each reaction mix was loaded on a SDS-PAGE 
gel and phosphorylated and non-phosphorylated substrates were separated on 
the gel. Proteins were detected by staining the gel with ‘Instant Blue-like’ solution.  
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3 Results 
 
To develop the computational protocol used in this thesis and to test its 
performance, we used different protein kinases from the scientific literature to 
which the Shokat’s method was applied. These kinases made up our data set 
containing 7 wild-type kinase proteins and 15 engineered kinases (Table 3.1). The 
ATP analogues were four N6-(substituent) ATPs with bulky hydrophobic groups at 
the N6 position of the adenine ring and the pyrazolopyrimidine PP1, as shown in 
Figure 3.1. 
 
 
 
Figure 3.1. Chemical structures of N6-(substituent) ATPs and PP1. For simplicity, only 
the structures of the adenine ring and the hydrophobic groups are reported. 
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Table 3.1. Percentage of substrate phosphorylation by ATP, catalytic efficiency 
(kcat/Km), IC50 and predicted interaction energy for each protein-ligand pair. 
Kinases Ligands Experimental 
data 
Predicted 
interaction energies 
(kcal/mol) 
v-Src tyrosine kinase 
[18] 
 kcat/Km(min-1M-1)  
v-Src ATP 1.6 * 105 -21.35 
v-SrcI338A  1.4*104 -19.91 
v-SrcI338G  1 * 104 -19.01 
v-Src N6-(benzyl) ATP 0 0a) 
v-SrcI338A  2.5 * 104 -14.92 
v-SrcI338G  4.0 * 104 -29.17 
JNK kinase [27]  % substrate 
phosphorylation 
by ATP  
 
JNK N6-(benzyl)  99 0 a) 
 N6-(2-phenythyl)  98 0 a) 
 N6-(cyclopentyl)  97 0 a) 
 N6-(1-methylbutyl)  93 0 a) 
    
JNKM108GL168A N6-(benzyl) 62 -17.34 
 N6-(cyclopentyl) 59 -14.42 
 N6-(1-methylbutyl) 47 -20.42 
 N6-(2-phenythyl) 8 -33.0 
Tyrosine and 
serine/threonine 
kinases [102] 
 IC50(M)   
v-Src PP1 5 ± 2 0 a) 
v-SrcI338F  8 ± 2 0 a) 
v-SrcI338M  8 ± 1 0 a) 
v-SrcI338S  0.4 ± 0.05 -28.78 
v-SrcI338T  0.1 ± 0.02 -33.32 
v-SrcI338V  0.1 ± 0.02 -27.41 
v-SrcI338C  0.07 ± 0.02 -27.44 
v-SrcI338A  0.005 ± 0.002 -39.26 
v-SrcI338G  0.005 ± 0.002 -38.56 
Fyn  0.05 ± 0.02 -36.81 
FynT339A  0.005 ± 0.002 -36.21 
Abl  0.3 ± 0.03 -32.93 
AblT334A  0.03 ± 0.005 -33.86 
CamKII  80 ± 10 0 a) 
CamKIIF89G  0.5 ± 0.1 -15.74 
Cdk2  50 ± 10 0 a) 
Cdk2F80G  0.16 ± 0.03 -24.85 
P38  0.82 ± 0.2 -34.61 
P38T106A  0.0027 ± 0.005 -33.43 
P38T106G  0.0027 ± 0.005 -32.78 
a) positive interaction energies approximated to 0. 
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We used our in silico protocol to explore pairings of potential mutations and ligand 
analogues by identifying which residues within the binding pocket of the target 
protein could to be mutated to accommodate a specific ATP analogue. The 
predicted interactions between engineered kinases and ATP analogues were 
compared with the published data.  
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3.1 v-Src and N6-(benzyl) ATP 
 
To develop and test the performance of our approach, we firstly used it with the 
system studied by Shokat and coworkers in 1997, v-Src and the N6-(benzyl) ATP 
[18]. Shokat and coworkers engineered the v-Src ligand-binding pocket to 
generate a kinase mutant that preferentially used N6-(benzyl) ATP as 
phosphodonor instead of the natural nucleotide, ATP. They showed that the    
wild-type protein had a substrate preference for ATP over the ATP analogue (1.6 * 
105 min-1M-1 vs 0) whereas the I338G mutant preferentially used N6-(benzyl) ATP 
as nucleotide over the natural ATP (the kcat/Km ratio was 4 to 1). The key finding 
was that residue at position 338, Ile338, limited the ability of v-Src to bind to      
N6-(benzyl) ATP and the mutation of this residue into one with a smaller side 
chain (such as Gly) conferred on v-Src the capability to utilize the ATP analogue 
as substrate.  
We applied our protocol to that system. The wild-type v-Src and ANP (an ATP 
analogue with an amino group in place of the oxygen between  and  
phosphates) were used as input structures. An ensemble of 1040 N6-(benzyl) 
ATP conformers, obtained by a conformational search (see Methods), was 
analyzed in the context of the binding pocket of wild-type v-Src. Residues 
overlapping with the benzyl group at the N6 position of the adenine base were 
considered as potential candidates for single-point mutations. None of the 
conformers occupied the wild-type binding pocket without clashes and a collection 
of 43 conformers overlapped with single residues. The analysis of these 
conformers showed that they were organized in 2 main groups, a first one (32 
conformers) that clashed with Ile338 and a second one (11 conformers) that 
clashed with Leu393 (Figure 3.2). Residues Ile338 and Leu393 were 
computationally mutated into Gly in order to obtain v-SrcI338G and v-SrcL393G, 
respectively. We analyzed the interaction between v-Src mutants and N6-(benzyl) 
ATP conformers using three protein-ligand scoring functions, GlideScore [71],     
X-Score [72], and DSX [68]. Table 3.2 and 3.3 represent values obtained for       
v-SrcI338G and v-SrcL393G, respectively. For v-SrcI338G and the 32 N6-(benzyl) 
ATP conformers we got different results from the 3 scoring functions used.  
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Figure 3.2. The v-Src ligand-binding pocket (represented as a molecular surface) and the 
two main groups of clashing conformers. The conformers that clash with Ile338 and 
Leu393 are represented in orange and green, respectively.  
 
 
According to GlideScore only 4 conformers bound to the engineered kinase 
(negative interaction energies), for X-Score all conformers bound to v-SrcI338G 
and DSX identified 27 conformers having favorable interaction energies with the 
kinase mutant (Table 3.2). To understand the different results obtained, we 
visually inspected the 32 conformers within the engineered binding site of            
v-SrcI338G. Figure 3.3 represents a N6-(benzyl) ATP conformer within the binding 
pocket of v-SrcI338G. As we can see, the benzyl ring clashed with backbone 
atoms of Gly338 and Glu339. The GlideScore for that mutant-analogue pair is    
10 000 kcal/mol, the X-Score is 5.25 and the DSX is -22.945 kcal/mol. Only 
GlideScore identified the conformer as a bad one in agreement with the observed 
clashes between the protein and the ligand. Similarly, for v-SrcL393G and the 11 
51 
 
N6-(benzyl) ATP conformers we got different results from the three different 
scoring functions (Table 3.3). 
 
Table 3.2. GlideScore, X-Score, and DSX values for v-SrcI338G and N6-(benzyl) ATP 
conformers. 
 v-SrcI338G overlapping conformers  
(32 conformers) 
1 to 4 5 to 32 
GlideScore (kcal/mol) -8.67 to -6.84 10 000 
   
 1 to 32 - 
X-Score (pkd units) 5.61 to 5.01 - 
   
 1 to 27 28 to 32 
DSX (kcal/mol) -75.03 to -22.95 > 0 
 
 
Table 3.3. GlideScore, X-Score, and DSX values for v-SrcL393G and N6-(benzyl) ATP 
conformers. 
 v-SrcL393G overlapping conformers  
(11 conformers) 
1 to 11 - 
GlideScore (kcal/mol) 10 000 - 
   
 1 to 11 - 
X-Score (pkd units) 5.25 to 5.05 - 
   
 1 to 11 - 
DSX (kcal/mol) -49.90 to -12.56 - 
 
 
For GlideScore none of the 11 conformers can be accommodated by the 
engineered kinase binding site whereas for both X-Score and DSX all conformers 
can occupy the binding pocket. We visually inspected the 11 conformers within 
the v-SrcL393G ligand-binding pocket. Figure 3.4 represents a N6-(benzyl) ATP 
conformer within the binding pocket of v-SrcL393G. The benzyl ring clashed with 
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Ile338 and Ala403. Only GlideScore identified that conformer as a bad one 
(GlideScore was equal to 10 000 kcal/mol) whereas both X-Score and DSX were 
unable to detect clashes between engineered protein and ligand analogue, 
assigning favorable scores (5.18 and -45.90 kcal/mol, respectively).  
 
 
Figure 3.3. The v-SrcI338G ligand-binding pocket (represented as a molecular surface) 
and a N6-(benzyl) ATP conformer (represented as stick). The orange and red dashed 
lines represent “bad and ugly” protein-ligand contacts, respectively (Appendix A3). 
 
 
The analysis already described suggested us to use GlideScore as scoring 
function to evaluate and rank the kinase mutant-ligand conformer pairs. In that 
specific case, GlideScore provided favorable interaction energies for complexes of 
v-SrcI338G and four N6-(benzyl) ATP conformers (Table 3.2). At that point, we 
computed the relative free energies of binding for all complexes of v-SrcI338G 
and ligand conformers by using the MM-GBSA method. Here we reported the free 
energy of binding only for four complexes of v-SrcI338G and ligand conformers for 
which we previously got favorable GlideScores and two complexes of the 
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engineered v-Src and ligand conformers for which we got unfavorable 
GlideScores. In the last two complexes the N6-(benzyl) ATP conformers clashed 
with the engineered binding sites.  
 
 
Figure 3.4. The v-SrcL393G ligand-binding pocket (represented as a molecular surface) 
and a N6-(benzyl) ATP conformer (represented as stick). The orange and red dashed 
lines represent bad and ugly protein-ligand contacts, respectively (Appendix A3). 
 
 
Each complex was subjected to a molecular dynamics (MD) protocol with a 
production phase of 20 ns. To check the stability of the mutant-analogue 
complexes, for each of them the rmsd of the C atoms relative to the initial 
complex structure was monitored. Figure 3.5 represents the structures and the 
rmsd plots for a complex with a favorable GlideScore (A) and for a complex where 
the ligand clashes with the protein and for which we previously obtained an 
unfavorable GlideScore (B). The single trajectories obtained via MD simulations 
were used to compute the free energy of binding (G) for each mutant-analogue 
complex. Those values were compared to GlideScore values previously obtained 
(Table 3.4).  
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Figure 3.5. Molecular dynamics trajectory plots correlating rmsd deviation from the initial 
v-SrcI338GN6-(benzyl) ATP complex coordinates, over a simulation time of 20 ns (2000 
frames). A) v-SrcI338GN6-(benzyl) ATP with no protein-ligand clashes and the best 
GlideScore; B) v-SrcI338GN6-(benzyl) ATP with strong protein-ligand clashes and the 
worse GlideScore. In both complexes, only adenine moieties are represented. 
 
 
Table 3.4. GlideScore and G values for six v-SrcI338GN6-(benzyl) ATP complexes. 
The complexes are numbered from 1 to 6 according to GlideScore rank. 
Mutant-analogue complexes GlideScore(kcal/mol) G(kcal/mol) 
v-SrcI338N6-(benzyl)1 -7.67 -24.02 ± 2.43 
v-SrcI338N6-(benzyl)2 -7.58 -25.71 ± 2.40 
v-SrcI338N6-(benzyl)3 -7.38 -24.29 ± 2.37 
v-SrcI338N6-(benzyl)4 -6.84 -24.47 ± 2.77 
v-SrcI338N6-(benzyl)5 10 000 4.07 ± 2.30 
v-SrcI338N6-(benzyl)6 10 000 31.29 ± 2.25 
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The rmsd plots showed that the complex with a favorable GlideScore was stable 
during the production phase of the MD simulation (Figure 3.5 A). The rmsd 
showed a convergence after 2-4 ns (frames 200-400) in a range between 2 to 2.5 
Å. In that case the ligand did not significantly change its pose within the binding 
site. For the complex where the ligand overlaps the protein, after few 
nanoseconds the rmsd increased steeply (from ~ 5Å to ~20Å) and it continues to 
increase during the production phase (Figure 3.5 B). The ligand has moved away 
from the binding site and this might be a response to the initial unfavorable 
superposition between the protein and the ligand. The single trajectories obtained 
via MD simulations were used to compute the free energy of binding (G) for each 
mutant-analogue complex. Those values were compared to GlideScore values 
previously obtained (Table 3.4). The relative free energies of binding provided the 
same trend of the GlideScore values. The MM-GBSA results validated the ability 
of GlideScore to correctly predict the binding of a ligand to its target protein. 
GlideScore was therefore selected as protein-ligand scoring function in our 
computational protocol. 
As previously mentioned, in their first papers Shokat and coworkers found that the 
mutation of the gatekeeper residue Ile338 into Ala or Gly conferred to v-Src the 
ability to accommodate N6-(benzyl) ATP within the binding pocket [18, 134]. By 
applying our protocol, we identified Ile338 as a candidate for single-point mutation 
and evaluated the interaction of v-SrcI338A and v-SrcI338G with an ensemble of 
N6-(benzyl) ATP conformers. The most promising pair of kinase mutant and 
analogue conformer was the one with the best GlideScore. For that pair the Glide 
energy was taken into account and compared to the available kinetic data. The 
wild-type v-Src and both I338A and I338G mutants are predicted to bind to ATP 
with almost equal interaction energies (Figure 3.6 A). The wild-type v-Src does not 
accommodate N6-(benzyl) ATP because of the steric overlapping between Ile338 
and the benzyl ring at the N6 position (predicted interaction energy is 0 kcal/mol). 
The I338A and I338G mutants have an enlarged binding pocket and both mutants 
show favorable interaction with N6-(benzyl) ATP (Figure 3.6 B).  
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Figure 3.6 Comparison of the catalytic efficiency and predicted interaction energy for     
v-Src, v-SrcI338A, and v-SrcI338G with ATP (A) and with N6-(benzyl) ATP (B). Shown on 
the x-axis are the wild-type protein and the two mutants. The primary y-axis (on the left) is 
the predicted interaction energies multiplied by -1 and the secondary y-axis (on the right) 
is the log of the kcat/Km ratio. The red dashed lines represent the experimental data and 
the solid black lines represent predicted interaction energies. 
 
 
3.2 JNK and N6-(substituent) ATPs 
 
Habelhah and coworkers modified the JNK ATP binding site so that it bound to 
N6-(substituent) ATPs that cannot be accommodated by the wild-type binding 
pocket. The designed pair of engineered JNK and ATP analogue allowed for the 
identification of novel JNK substrates [27]. They identified two key residues to 
mutate within the JNK ligand-binding pocket, Met108 and Leu168. Those residues 
were mutated into Gly and Ala, respectively. To determine the ATP analogue with 
the highest affinity for the engineered JNK, they compared four N6-(substituent) 
ATPs, N6-(benzyl) ATP, N6-(2-phenythyl) ATP, N6-(cyclopentyl) ATP and         
N6-(1-methylbutyl) ATP (Figure 3.1). Their efficiency as phosphodonor was tested 
by measuring their ability to prevent phosphorylation of substrates by ATP when 
they are added in excess with respect to ATP. For JNK and the ATP analogues 
the percentage of substrate phosphorylation ranged from 99% to 93%, showing 
the inability of the wild-type kinase to accommodate any of the four ATP 
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analogues. On the other hand, the JNKM108GL168A mutant was able to 
accommodate N6-(substituent) ATPs and N6-(2-phenythyl) was the ligand with 
the highest affinity to the mutant (the percentage of substrate phosphorylation was 
8%) (Table 3.1).  
We applied our computational protocol on the system studied by Habelhah and 
coworkers. We used wild-type JNK and ANP as input structures - Figure 3.7 
represents the JNK ligand-binding pocket. For each of the four ATP analogues we 
performed a conformational search (as described in Methods) to obtain 
ensembles of low-energy conformers. The ensembles were analyzed within the 
binding site of wild-type JNK and results are shown in Table 3.5. All conformers of 
each ATP analogue clashed with diverse residues within the JNK ligand-binding 
pocket (Met108, Glu109, Leu110, Met111, Ala53, Ile86, and Leu206) implying that 
they cannot fit in the wild-type binding site. For each ATP analogue we identified 
diverse pairs of residues to be mutated into smaller residues to enlarge the 
binding site (Appendix A4).  
 
 
Figure 3.7. Wild-type JNK ligand-binding pocket (represented as a molecular surface), 
ANP (represented as line) and Mg2+ ions (represented as pink spheres). Residues 
Met108 and Leu168 are represented as sticks and occupy the upper and the lower part of 
the binding site, respectively. Amino acids from 108 to 111 make up the hinge region.  
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Table 3.5. Classification of conformers of N6-(benzyl) ATP, N6-(2-phenythyl) ATP,       
N6-(cyclopentyl) ATP and N6-(1-methylbutyl) ATP within the JNK ligand-binding pocket.  
 Total 
number of 
conformers 
Conformers 
with 0 
overlaps 
Conformers 
overlapping 
with 1 res. 
Conformers 
overlapping 
with 2 res. 
All 
others 
N6-(benzyl) 1040 0 27 269 744 
N6-(2-phenythyl) 965 0 22 227 716 
N6-(cyclopentyl) 380 0 1 70 309 
N6-(1-methylbutyl) 971 0 6 121 844 
 
 
We identified three double mutants that can accommodate the N6-(substituent) 
ATPs, M108GL168A, M108GI86A, and M108GA53G. Since experimental data 
were only available for the M108GL168A mutant, we focused on it and compared 
our findings with the percentage of substrate phosphorylation. We reproduced the 
relative ranking of the four ATP analogues as substrates for the engineered JNK 
(Figure 3.8). 
 
 
Figure 3.8. The percentage of substrate phosphorylation by ATP in presence of ATP 
analogues and the scaled predicted interaction energies for the engineered JNK and 
each of the four ATP analogues. The dashed red line represents the experimental data 
and the solid black line the predicted data. 
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3.3 Tyrosine and serine/threonine protein kinases and PP1 
 
PP1 is a potent inhibitor of Src protein kinases [135]. The first evidence that the 
ability of PP1 as Src kinases inhibitor was related to the nature of the gatekeeper 
residue came from the discovery that PP1 was a good inhibitor (0.7 M) of c-Src, 
where the gatekeeper residue is a Thr, and was a poor inhibitor (5 M) of v-Src, 
where the gatekeeper is an Ile. That finding suggested that the size of the side 
chain of the gatekeeper amino acid might be essential for the kinase inhibition 
from PP1. Liu and coworkers decided to test the relationship between the nature 
of the gatekeeper residue and the PP1 potency in two families of protein kinases, 
Src tyrosine and serine/threonine kinases [102]. Proteins studied are reported in 
Table 3.7. 
 
Table 3.7. Protein kinases studied by Liu and coworkers [102]. 
Src family protein 
kinases 
Serine/threonine protein 
kinases 
v-Src, Fyn, Abl CamKII, Cdk2, P38 
 
 
The gatekeeper amino acid is Ile338 in v-Src, Thr339 in Fyn, Thr334 in Abl, 
Phe89 in CamKII, Phe80 inCdk2, and Thr106 in kinase P38 (Figure 3.9). It was 
shown that in both families residues equal to or larger than Ile, such as Phe and 
Met, made PP1 a poor inhibitor whereas residues smaller than Ile, such as Ser, 
Thr, Val, Cys and especially Ala and Gly increased the potency of PP1.  
 
 
Figure 3.9. Sequence alignment of the N-lobe and hinge region of the seven wild-type 
protein kinases belonging to our data set. The alignment was build using the T-Coffee 
web server [136]. Residues are colored by percentage identity. The hinge region is 
designated with black triangles and the gatekeeper residues are colored in magenta. 
Secondary structure elements are represented as follows:  strands as arrows,  helices 
as cylinders, and coils as lines. 
60 
 
Table 3.8 shows results obtained using our computational protocol with the seven 
kinases and PP1. 
 
Table 3.8. Classification of the PP1 conformers within the binding sites of v-Src, Fyn, Abl, 
CamKII, Cdk2 and P38 
Wild-type kinase and 
gatekeeper residue 
Total number 
of conformers 
Conf. with 
0 overlaps 
Conf. overlapping 
with 1 residue 
All 
others 
v-Src (I338) 1000 0 1000 0 
Fyn (T339) 1000 1000 0 0 
Abl (T334) 1000 1000 0 0 
CamKII (F89) 1000 0 717 283 
Cdk2 (F80) 1000 0 1000 0 
P38 (T106) 1000 1000 0 0 
 
 
Wild-type v-Src, CamKII and Cdk2 cannot accommodate PP1 within their binding 
pocket. All 1000 conformers overlapped with a single residue within the binding 
site. Those residues are Ile338 of v-Src, Phe89 of Cdk2 and Phe80 of Cdk2 that 
clashed with the hydrophobic ring of all 1000 PP1 conformers. Those results 
agreed with IC50 values > 1 M (Table 3.1).  
 
 
Figure 3.10. A) Wild-type Cdk2 ligand-binding pocket (represented as a molecular 
surface) and a PP1 conformer (represented as line). B) Wild-type P38 ligand-binding 
pocket (represented as molecular surface) and a PP1 conformer (represented as line). 
Phe89 and Thr106 are represented as sticks and protein-ligand clashes as dashed red 
lines (Appendix A3). 
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Figure 3.10 A represents a PP1 conformer within the Cdk2 binding site. The side 
chain of Phe89 and the tolyl ring of PP1 clashed to each other. On the other hand, 
the Thr naturally presents in the wild-type Fyn, Abl and P38 did not clash with any 
PP1 conformer. PP1 can be accommodated within the binding site of the three 
kinases and that finding agreed with IC50 values ranging from 0.05 M to 0.82 M 
(Table 3.1). Figure 3.10 B represents a PP1 conformer within the P38 binding site. 
Thr106 and the hydrophobic ring of PP1 did not overlap. 
For each of the six protein kinases, we computationally mutated the gatekeeper 
residues in order to obtain the 14 mutants studied in Liu’s work. For both kinases 
families the predicted energies of interaction between proteins and inhibitor 
estimated the trend of the inhibitor potency (Table 3.1). Moreover, we obtained a 
positive correlation between the experimental –log(IC50), the pIC50, and the 
predicted interaction energies, with a Pearson correlation of 0.85 for Src tyrosine 
kinases and of 0.75 for serine/threonine kinases (Figure 3.11 A and B).  
 
 
Figure 3.11. Correlation plots of the predicted interaction energies versus the 
experimental pIC50. (A) Src family tyrosine kinases with PP1. (B) Serine/threonine kinases 
with PP1 (B). 
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3.4 Experimental application 
 
We apply our computational protocol to the Mycobacterium tuberculosis 
serine/threonine protein kinase G (Mtb PknG). Nowadays, several studies have 
proved the significant role of PknG in the survival of Mtb within the host 
macrophage. Nonetheless, PknG downstream substrates involved in the infection 
pathway are still unknown. These open questions make PknG an attracting target 
to which apply our computational approach. Figure 3.12 represent the kinase 
domain of PknG in complex with ATP.  
 
 
Figure 3.12. Structure of the PknG kinase domain (gray ribbon) in complex with ATP 
(gray stick). The structure is shown with a zoom-in into the binding site. It is represented 
as a surface where the adenine region is colored in cyan, the sugar region in green, the 
phosphates region in violet, the buried region in blue and the solvent accessible region in 
yellow. 
 
 
We aim to identify residues to mutate within the PknG ligand-binding site to 
generate mutants that are still catalytically active and can specifically use ATP 
analogues as phosphodonor. We used five purchasable ATP analogues, two with 
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a conserved chemistry with respect to the analogues used by Shokat and 
coworkers (hydrophobic groups at the N6 position of the adenine ring, N6-(methyl) 
ATP and N6-(benzyl) ATP) (Figure 3.13 A) and three with different chemistry 
(groups on different positions of the adenine ring, 8-Azido ATP, 2-(phenylethyl) 
ATP, (PF9) and 7-deaza-7propargylamino-ATP (7d7p ATP)) (Figure 3.13 B). We 
applied our computational protocol on PknG and the five ATP analogues, and the 
predictions made were experimentally tested. 
 
 
Figure 3.13 A and B. Chemical structures of the ATP analogues used with PknG. For 
simplicity, only the adenine base is represented. Black circles highlight positions at which 
substituent groups are attached. 
 
 
3.4.1 PknG and N6-(methyl) ATP 
The ensemble of N6-(methyl) ATP conformers, 890 conformers, was analyzed 
within the wild-type PknG binding site. Of the total ensemble, a group of 101 
conformers occupied the ligand-binding site of wild-type PknG without any clash 
(Figure 3.14). The methyl group of the ATP analogue was small enough to 
accommodate the wild-type binding pocket without overlapping with any residue. 
N6-(methyl) ATP was predicted to bind to PknG and would not be a specific ATP-
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competitive ligand for an engineered PknG. These results made N6-(methyl) ATP 
an inadequate candidate for our aim and it was discarded.  
 
 
Figure 3.14. The wild-type PknG ligand-binding pocket (represented as a molecular 
surface) and N6-(methyl) ATP conformers that do not overlap with any binding-site 
residues (represented as stick). For simplicity, only the adenine rings are represented. 
 
 
3.4.2 PknG and N6-(benzyl) ATP 
An ensemble of N6-(benzyl) ATP conformers (1040 conformers) was analyzed 
within the binding pocket of wild-type PknG. We investigated if the wild-type 
protein could accommodate some conformers without any clash or it needed to be 
engineered. The PknG binding pocket was not large enough to accommodate an 
ATP analogue with a benzyl group at the N6 position of the adenine base. A 
number of 53 conformers, over the total ensemble, overlapped 2 residues within 
the ligand-binding pocket. A group of 52 conformers clashed with Met232 placed 
in the upper part of the binding site and the remaining conformer clashed with 
Val211 situated in the lower part of the pocket (Figure 3.15).  
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Figure 3.15. PknG ligand-binding pocket (represented as a molecular surface) and the 
two groups of overlapping conformers (represented as lines). Conformers that clash with 
Met232 and Val211 are represented in green and red, respectively.  
 
 
We engineered the PknG binding site by mutating Met232 and Val211 into Gly in 
order to obtain PknGM232G and PknGV211G mutants. Even though the 
mutagenesis of Val211 into a smaller Gly introduced an additional space in the 
lower part of the binding site, it was still not large enough to accommodate the  
N6-(benzyl) ATP conformer. The hydrophobic group of the ATP analogue clashed 
with backbone atoms of Gly211 and Gln212 (Figure 3.16). Additionally, the 
analogue clashed with the side chain of Met232 suggesting the important role of 
that amino acid in defining the size of the binding site and in regulating the access 
of N6-(benzyl) ATP. The energy of interaction of PknGV211G and N6-(benzyl) 
ATP was unfavorable, at 18.04*107 kcal/mol.  
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Figure 3.16. PknGV211G ligand-binding pocket (represented as a molecular surface) 
and N6-(benzyl) adenine conformer (represented as lines). The orange and red dashed 
lines represent “bad and ugly” protein-ligand contacts, respectively (Appendix A3). 
 
 
The M232G mutant interacted with one N6-(benzyl) ATP conformer with a 
negative GlideScore (-6.50 kcal/mol) and thus a favorable interaction energy       (-
24.20 kcal/mol). The mutagenesis of Met232 into Gly created an additional pocket 
otherwise occupied by the polar side chain of Met. The enlarged binding site 
enabled the accommodation of N6-(benzyl) ATP. The adenine base was involved 
in a hydrogen bond (H-bond) with the Val235 whereas the hydrophobic group was 
involved in hydrophobic interactions with four non polar residues, Val179, Val211, 
Ile213 and Ile230 (Figure 3.17).  
Our prediction was experimentally tested. An in vitro kinase assay was performed 
to assess the ability of PknGM232G to bind N6-(benzyl) ATP and use it as         
co-substrate. The assay was performed at different concentrations of cofactors 
(from 200 M to 10 M) (Figure 3.18). 
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Figure 3.17. PknGM232G ligand-binding pocket (represented as a molecular surface) 
and N6-(benzyl) adenine conformer (represented as lines). Polar hydrogen are colored in 
white. The yellow dashed line represents the protein-ligand H-bond. Residues involved in 
hydrophobic interactions are represented as darker molecular surface (Val179, Ile230, Ile 
213 and Val211) (Appendix A3). 
 
 
Figure 3.18. In vitro kinase assay (SDS-PAGE) using GarA as substrate, wild-type 
PknGN (WT) or PknGN-M232G (M232G) and ATP or N6-(benzyl) ATP (N6B) as 
cofactors. GarA-P is the phosphorylated GarA. The symbol Ø means that neither ATP nor 
N6B are used in those lanes.  
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The gel showed that PknGM232G was catalytically active and the single point 
mutation did not affect its kinase activity. Both PknG and PknGM232G 
phosphorylated GarA using ATP as phosphodonor and the activity of the mutant 
was lower than that one of the wild-type, especially at low concentrations of ATP. 
At concentrations of 200 M and 100 M, PknGM232G showed a significant 
activity with the ATP analogue. In the range from 50 M to 10 M PknGM232G 
used N6-(benzyl) ATP as phosphodonor to phosphorylate GarA and its kinase 
activity with N6-(benzyl) ATP was higher than with natural ATP. The kinase assay 
was repeated twice and both experiments showed the same results. 
 
 
3.4.3 PknG and 8-Azido ATP 
The 8-Azido ATP is an ATP analogue with an azide ion at the position C8 of the 
adenine ring (Figure 3.13). An ensemble of 1000 8-Azido ATP conformers was 
analyzed within the ligand-binding pocket of wild-type PknG. A group of 
conformers accommodated the wild-type ligand-binding site without any overlap 
meaning that 8-Azido ATP is expected to act as substrate in wild-type kinase 
(Figure 3.19). The 8-Azido ATP was not a suitable ligand for our goal.  
The analysis of the 8-Azido ATP conformers within the PknG binding site allowed 
for a more general remark. For all conformers, azide ions occupy the region of the 
ATP binding site generally involved in the binding of phosphates, ‘phosphatases 
region’. In more detail, 356 conformers clashed with Lys181 and a group of 340 
conformers overlapped Ile292 and Asp293. Lys181 and Asp293 are highly 
conserved in all tyrosine and serine/threonine protein kinases, they specifically 
interact with phosphates and have a significant role in the kinase catalytic activity 
[44]. The mutation of one of them into another residue would disrupt the ability of 
the protein kinase to phosphorylate its specific substrate resulting in an inactive 
engineered kinase. Since we aimed to change the kinase co-substrate specificity 
without affecting its catalytic activity, Lys181 and Asp293 would not be good 
candidate for mutagenesis. Those observations pointed out that it is of great 
importance always check the role of residues identify as potential candidate for 
mutagenesis before transforming them.  
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Figure 3.19. The wild-type PknG ligand-binding pocket (represented as a molecular 
surface) and 8-Azido ATP conformers without overlaps (represented as lines). Residues 
232-235 formed the hinge region involved in the binding of the adenine ring. Lys181 and 
Asp293 (catalytic residues) are represented as stick. 
 
 
3.4.4 PknG and PF9 
The 2-(phenylethynyl) ATP (PF9) is an ATP analogue characterized by the 
presence of the non-polar phenylethynyl group at the position C2 of the adenine 
ring (Figure 3.13). An ensemble of 1000 low energy conformers of PF9 was 
analyzed within the ligand-binding pocket of the wild-type PknG. A group of 15 
conformers clashed with 2 residues within the binding pocket, Val235 which 
overlapped with 14 conformers and Tyr234 which overlapped with 1 conformer. 
Val235 and Tyr234 were mutated in silico to Gly to obtain the V235G and Y234G 
mutants, respectively. The predicted interaction energies of the PknG mutants and 
the PF9 conformers are shown in Table 3.8.  
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Table 3.8. GlideScore values of PknGV235G and PknGY234G with PF9 conformers. 
 PknGV235G conformers  
(14 conformers) 
PknGY234G conformer 
(1 conformer) 
1, 2  3 to 14 1 
GlideScore (kcal/mol) -5.94, -4.9 10 000 10 000 
 
 
The mutagenesis of Tyr234 into Gly did not allow the accommodation of PF9 
within the engineered binding site. On the other hand, among the group of 14 
conformers 2 occupied the V235G binding pocket with favorable GlideScores. The 
mutant-analogue pair with the best GlideScore had an interaction energy of           
-23.3 kcal/mol. The phenylethynyl group of PF9 was involved in favorable 
hydrophobic interactions with the side chain of Ile157 and the aromatic ring of 
Tyr234 (Figure 3.20).  
 
 
Figure 3.20. The PknGV235G ATP binding pocket (represented as a molecular surface) 
and the PF9 conformer with best GlideScore (represented as stick). Residues involved in 
hydrophobic interactions are represented as darker molecular surface (Tyr234 and 
Ile157). Gly235 (the mutated residue) is represented as stick. 
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The kinase assay was performed to experimentally test our prediction. The gel 
shows the phosphorylation activity of both PknG and PknGV235G in presence of 
native ATP or PF9 (Figure 3.21). 
 
 
Figure 3.21. In vitro kinase assay (SDS-PAGE) using GarA as substrate, wild-type 
PknGN (WT) or PknGN-V235G (V235G) and ATP or PF9 as cofactors. GarA-P is the 
phosphorylated GarA. The symbol Ø means that neither ATP nor PF9 are used in those 
lanes.  
 
 
The assay was performed using several cofactor concentrations (200 M to 10 
M). The mutagenesis of Val235 into Gly did not affect the catalytic activity of the 
protein kinase. The engineered PknGV235G was able to phosphorylate GarA in 
presence of ATP at all concentrations. It was not possible to discriminate between 
the activity of PknG and PknGV235G in presence of PF9, both proteins had an 
insignificant phosphorylation activity in presence of PF9. In addition, at all 
concentrations PknGV235G had a high kinase activity in presence of native ATP, 
comparable to the phosphorylation activity of the wild-type protein in presence of 
ATP.  
 
 
3.4.5 PknG and 7d7p ATP 
The 7-deaza-7propargylamino ATP (7d7p ATP) has a propargylamine group at 
position C7 of the deazapurine ring where a nitrogen atom (N7) is replaced by a 
carbon atom (C7) (Figure 3.13). An ensemble of 1000 low energy conformers of 
7d7p ATP clashed with only one residue within the PknG ligand-binding pocket, 
Met232. Figure 3.22 shows the ensemble of 7d7p ATP conformers within the  
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wild-type PknG binding pocket. All propargylamines pointed to the buried region of 
the ligand-binding pocket that is placed on the back of the ATP pocket and is 
generally not occupied by the ATP [39]. 
 
 
Figure 3.22. The wild-type PknG ligand-binding pocket (represented as a molecular 
surface) and 7d7p ATP conformers (represented as lines). Residues 232-235 formed the 
hinge region. Met232 is represented as stick. 
 
 
The 7d7p ATP contains a –NH2 group which is an H-bond donor and acceptor. 
We decided to mutate Met232 into residues that could be specifically involved in 
H-bonds. Met232 was changed into His, Ser and Thr in order to obtain three 
PknG mutants, M232H, M232S and M232T. The imidazole ring of a neutral His 
can act as H-bond donor (with the polar hydrogen) and H-bond acceptor (with the 
basic nitrogen) and hydroxyl groups of both Ser and Thr can act as donor and 
acceptor in H bonds (Figure 3.23). All pairs of PknGM232H and 7d7p ATP had 
positive GlideScores indicating unfavorable protein-ligand interaction. The 
mutagenesis of Met232 into His means changing a polar side chain into another 
that can be involved in H-bonds. On the other hand, Met and His side chain are 
almost equal in size (171 Å3 vs 167Å3) [137]. His at position 232 blocks the 
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access to the buried region preventing all 7d7p ATP conformers to occupy the 
PknGM232H ligand-binding site. Figure 3.24 represents the 7d7p ATP conformer 
with the worst interaction energy within the PknGM232H binding site (13.63*107 
kcal/mol). 
 
 
Figure 3.23. Three-dimensional structures of His, Ser and Thr. H-bond donor and H-bond 
acceptor are highlighted by black and orange circles, respectively. 
 
 
 
Figure 3.24. The PknGM232H ligand-binding pocket (represented as a molecular 
surface) and the 7d7p ATP conformer with the worst interaction energy (represented as 
lines). His232 is represented as stick and residues 232-235 represent the hinge region. 
Red dashed lines represent “ugly” protein-ligand contacts (Appendix A3). 
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Table 3.9 shows the results of the analysis of protein-ligand interactions for 
PknGM232S and PknGM232T with the 7d7p ATP conformers. The engineered 
PknGM232S had favorable GlideScores for 562 conformers whereas PknGM232T 
showed favorable interactions with 19 conformers. 
 
Table 3.9. GlideScore values of PknGM232S and PknGM232T with 7d7p ATP 
conformers. 
 PknGM232S conformers  
(1000 conformers) 
PknGM232T conformer 
(1000 conformer) 
1 to 562  others 1 to 19 others 
GlideScore (kcal/mol) -4.92 to -3.95 10 000 -5.18 to -1.42 10 000 
 
 
Figure 3.25 A and B represent the complexes of PknGM232S and 7d7p ATP and 
PknGM232T and 7d7p ATP with the best GlideScores (energies of interaction 
equal to -10 kcal/mol and -7.03 kcal/mol, respectively).  
Within the PknGM232S-7d7p ATP complex, Ser232 modelled to be involved in an 
H-bond with the deazapurine ring (nitrogen N6) together with Glu233 and Val235 
(with N6 and N1, respectively). The primary amine of 7d7p ATP was predicted to 
be involve in two H-bonds with backbone nitrogens of Leu294 and Gly295 (Figure 
3.25 A). The mutagenesis of Met232 into the smaller Ser allowed some 
conformers to access the buried region of the ligand-binding pocket. On the other 
hand, Ser232 modelled to be involved in a specific H-bond with the deazapurine 
ring and not with the propargylamine of the ATP analogue. Among the 562 
conformers that favorably interacted with the engineered PknGM232S, some of 
them were characterized by the presence of H-bonds between Ser232 side chain 
and the propargylamine. Figure 3.25 C represents the complex of PknGM232S 
and 7d7p ATP with a specific H-bond between Ser232 and the propargylamine 
and the more favorable GlideScore (-4.52 kcal/mol). The interaction energy for 
such complex was -6.61 kcal/mol, a bit lower than the energy of interaction 
between the mutant and the conformer with the best GlideScore (-10 kcal/mol).  
The mutation of Met232 into Thr enlarged the ligand-binding pocket making the 
buried region accessible to some 7d7p ATP conformers. Figure 3.24 B shows the 
complex of the engineered PknGM232T in complex with a 7d7p ATP conformer 
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for which we got the best GlideScore. The hydroxyl group of Thr232 acted as     
H-bond donor interacting with N6 on the deazapurine ring. The –NH2 group of 
7d7p ATP formed H-bonds with the backbone nitrogen of Leu294 and the 
backbone oxygen of Ile292 (Figure 3.24 B). Analyzing all mutant-analogue pairs 
with favorable GlideScores, we found that Thr232 is always involved in H-bonds 
with the deazapurine moiety and not the propargylamine of 7d7p ATP. 
 
 
Figure 3.25. A) The PknGM232S ligand-binding pocket (represented as a molecular 
surface) and the 7d7p ATP conformer with the best GlideScore (represented as line). B) 
The PknGM232T ligand-binding pocket (represented as a molecular surface) and the 
7d7p ATP conformer with the best GlideScore. C) The PknGM232S ligand-binding pocket 
(represented as a molecular surface) and the 7d7p ATP conformer where the 
propargylamine interacts with Ser232 (represented as line). Residues involved in the     
H-bonds are represented as sticks. Polar hydrogens are colored in white. Yellow dashed 
lines represent protein-ligand H-bonds (Appendix A3). For each conformer only the 
deazapurine ring is represented. 
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The ability of PknGM232S and PknGM232T to use 7d7p ATP as cofactor was 
experimentally tested (Figure 3.26 A and B). Similar results were obtained for 
PknGM232S and PknGM232T. The mutagenesis of Met232 into Ser or Thr did not 
affect the kinase activity of the protein as both mutants showed a phosphorylation 
activity. At all concentrations 7d7p ATP acted as co-substrates for PknGM232S 
and PknGM232S but not for wild-type PknG. While 7d7p ATP specifically bound 
to the two engineered PknG and not to the wild-type kinases, PknGM232S and 
PknGM232T can use both native and analogue ATP as phosphodonor. Their 
phosphorylation ability was almost the same with the native ATP and the ATP 
analogue, even at low ligand concentrations. The experiments were repeated 
twice and the second one confirmed the first result obtained. 
 
 
Figure 3.26. In vitro kinase assay (SDS-PAGE) using wild-type PknGN (WT), PknGN-
M232S (M232S) (A) and PknGN-M232T (M232T) (B), GarA as substrate and ATP or 
7d7p ATP (7d7p) as cofactors. GarA-P is the phosphorylated GarA. The symbol Ø means 
that neither ATP nor 7d7p are used in those lanes.  
 
In the method developed by Shokat and coworkers, the gatekeeper residue is 
always converted into a small amino acid, generally Gly or Ala, to enlarge the 
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ligand-binding site that can accept ligands with bulky substituent groups. Applying 
our computational protocol on PknG and 7d7p ATP, we identified Met232, the 
gatekeeper residue, as potential candidate for single-point mutagenesis. We 
mutated Met232 into Ser and Thr in order to enlarge the ligand-binding site and to 
also take the advantage of their ability to participate to H-bonds. We compared 
the PknGM232S7d7p ATP and PknGM232T7d7p ATP complexes to the 
complex of a Shokat-like mutant, PknGM232G, and 7d7p ATP. Figure 3.27 A, B 
and C represent the interaction of PknGM232S, PknGM232T and PknGM232G 
with 7d7p ATP conformers for which we got the best GlideScores. In both 
PknGM232S and PknGM232T, Ser and Thr are involved into H-bonds with the 
deazapurine ring. Moreover, the methyl group of Thr232 is involved in a 
hydrophobic interaction with the triple bond of the propargylamine group. In the 
PknGM232G7d7p ATP complex, Gly232 is not involved in any specific 
interaction. The mutagenesis of Met232 into Gly just enlarges the binding pocket 
allowing 7d7p ATP to fit in the engineered pocket. That analysis showed that 
PknGM232S and PnkGM232T were involved into specific interactions with 7d7p 
ATP with respect to the Shokat-like mutant, PknGM232G. Those outcomes were 
tested by in vitro kinase assays (Figure 3.28 A and B). The three mutants 
(PknGM232G, PknGM232S and PknGM232T) used ATP as cofactor to 
phosphorylate GarA. At concentration values ranging from 200 M to 50 M, 
PknGM232S and PknGM232T used 7d7p ATP as co-substrate whereas 
PknGM232G did not show any catalytic activity in presence of the ATP-
competitive ligand.  
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Figure 3.27. A) The PknGM232S ligand-binding pocket resides and the 7d7p ATP 
conformer with the best GlideScore (represented as lines). Ser232 is represented in balls 
and sticks. B) The PknGM232T ligand-binding pocket resides and the 7d7p ATP 
conformer with the best GlideScore (represented as lines). Thr232 is represented in balls 
and sticks. C) The PknGM232G ligand-binding pocket resides and the 7d7p ATP 
conformer with the best GlideScore (represented as lines). Gly232 is represented in balls 
and sticks. Polar hydrogens are colored in white. Yellow dashed lines represent protein-
ligand H-bonds and gray dashed lines represent protein-ligand hydrophobic interactions 
(Appendix A3). Only the deazapurine ring is represented. 
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Figure 3.28. In vitro kinase assay (SDS-PAGE) using PknGN-M232S (M232S), 
PknGN-M232G (M232G) (A) and PknGN-M232T (M232T), PknGN-M232T (M232T) 
(B), GarA as substrate and ATP or 7d7p ATP (7d7p) as cofactors. GarA-P is the 
phosphorylated GarA. The symbol Ø means that neither ATP nor 7d7p are used in those 
lanes.  
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4 Discussion 
 
We use the method developed by Shokat and coworkers [18, 134] as starting 
point to develop a computational protocol for protein engineering. Our protocol 
aims to identify binding-site residues of the target kinase that could be mutated to 
accommodate a specific ATP analogue as co-substrate, without interfering with 
the catalytic activity of the kinase protein. It could be used as prescreening step in 
the context of the complex process of kinase protein substrate identification.  
 
 
4.1 Evaluation of the protein-ligand interaction  
 
The protocol is organized in two parts. The first part consists in the prediction of 
residues to mutate within the ligand-binding site of the protein kinase of interest to 
generate kinase mutants. The second part is the evaluation of the interaction 
between kinase mutants and ligand analogues by a protein-ligand scoring function 
(Figure 2.1).  
To identify the best protein-ligand scoring function for our protocol, we tested 
three different scoring functions, GlideScore, X-Score and DSX. The system 
studied by Shokat and coworkers in their first papers, v-Src and N6-(benzyl) ATP, 
was used to test the three scoring functions. We identified v-SrcI338G being a 
potential candidate for v-Src engineering. The interaction of v-SrcI338G with a 
group of N6-(benzyl) ATP conformers was evaluated by the three scoring 
functions. Only GlideScore was able to distinguish between conformers that 
occupied the engineered binding pocket without any clash and those clashing with 
residues belonging to the engineered binding site. We think that the reason why 
X-Score and DSX did not detect some protein-ligand clashes is due to their Van 
der Waals (vdW) interactions terms as compared to the GlideScore vdW term. In 
GlideScore, the vdW term is given by the Lennard-Jones 12-6 equation (equation 
2.7) and both heavy and hydrogen atoms contribute to the term. In X-Score, the 
vdW term is described by a ‘softer’ Lennard-Jones 8-4 potential (equation 2.12) 
and only heavy atoms contribute to this term. Moreover, to avoid huge repulsion 
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due to overlapping atom pairs there is an upper limit for the vdW term. For all 
pairs of atoms that exceed that limit the vdW term is cut flat to the upper limit 
value. For that reason X-Score is not particularly good in identifying protein-ligand 
clashes [72]. Lastly, the DSX distance-dependent pair potential is characterized 
by the fact that in case of low contact distances and overlaps the density function 
of the reference state is not well defined because no structural data are available 
in this distance range neither in PDB nor in CSD. For that reason, DSX is much 
better in rescoring poses obtained by docking programs that already identify and 
eliminate poses with protein-ligand clashes [68]. We found that the analysis of the 
vdW terms in the three different scoring functions well explain the different results 
obtained and justify the choice of GlideScore as scoring function in the evaluation 
part of the protocol. 
In the case of v-Src and N6-(benzyl) ATP, GlideScore allows for the identification 
of four N6-(benzyl) ATP conformers that favorably interact with the engineered v-
SrcI338G (Table 3.4). We then performed MM-GBSA calculations to further 
confirm those findings. For each v-SrcI338GN6-(benzyl) ATP pair, GlideScore 
focusses on a single bound conformation whereas the MM-GBSA approach uses 
MD simulations to generate an ensemble of bound conformations. There is an 
agreement between GlideScore and MM-GBSA results (Table 3.4). In general, 
MM-GBSA has a lower computational costs compared to FEP and TI and 
provides a more sophisticated computation of free energy compared to common 
scoring functions. Simple scoring functions may neglect significant contribution to 
the final energy [138]. Moreover, it has been proven that the best results are 
obtained when MM-GBSA is applied to an ensemble of ligands with high structural 
similarity, such as ligand conformational isomers [139-141]. N6-(benzyl) ATP 
conformers are isomers that can be interconverted by rotation around single 
bonds of the substituent group and thus they are suitable ligands to which apply 
MM-GBSA calculations. By applying MM-GBSA on such an ensemble, we can 
distinguish conformers that can accommodate the ligand-binding site from those 
that do not fit within the binding pocket. Those results confirm the GlideScore 
findings, supporting our choice of using GlideScore as protein-ligand scoring 
function in our computational strategy. 
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4.2 Application of the computational protocol 
 
In the first part of the thesis, the protocol was tested on different tyrosine and 
serine/threonine protein kinases from the scientific literature where Shokat’s 
method was applied and experimental data were available. The strategy well 
distinguishes residues that prevent the access of ATP-competitive ligands within 
the binding site, such as Ile338 of v-Src whose side chain preclude the 
accommodation of N6-(benzyl) ATP, from residues that do not interfere with the 
accommodation of analogues, such as Thr339 of Fyn which allow the binding of 
PP1 without being mutated. The method correlates well with published 
experimental data available for the tested protein kinases. The predicted 
interaction energies of v-Src, v-SrcI338A and v-SrcI338G with ATP and             
N6-(benzyl) ATP have the same trend as the kcat/Km ratio (Figure 3.6 A and B). 
Given N6-(benzyl) ATP, v-SrcI338G is identified as the best binder to the ATP 
analogue in agreement with experimental findings of Shokat [142]. Wild-type JNK 
does not accommodate any of the four N6-(substituent) ATPs and Met108 and 
Leu168 within JNK binding pocket are identified as potential candidates for double 
mutagenesis. Our method allows for the selection of N6-(2-phenythyl) ATP as the 
best ATP analogue to bind the engineered JNKM108GL168A (Figure 3.8) and 
that finding agrees with the experimental identification of N6-(2-phenythyl) ATP as 
the analogue with the highest affinity to the engineered JNK [27]. For both Src 
tyrosine and serine/threonine kinase families we obtain a good correlation 
between the experimental pIC50 and the predicted interaction energies, with 
correlation coefficient of 0.85 and 0.75, respectively (Figure 3.11 A and B). The 
predicted energies of interaction sufficiently estimate the trend of the inhibitor 
potency. In the case of PP1, the strategy discriminates well between proteins or 
mutants that are inhibited by the ligand analogue, such as Fyn or CamKIIF89, and 
proteins or mutants that are not inhibited, like the cases of Cdk2 or v-SrcI338F 
(Table 3.1). 
In the second part of the thesis, we apply our computational protocol on PknG and 
five purchasable ATP analogues (N6-(methyl) ATP, N6-(benzyl) ATP, 8-Azido 
ATP, PF9 and 7d7p ATP). We aimed to identify residues to mutate within the 
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PknG ligand-binding site to generate mutants that are catalytically active and that 
specifically and preferentially use ATP-competitive ligands as phosphodonors. 
Table 4.1 shows the results obtained. 
 
Table 4.1. Computational predictions and results of in vitro kinase assays for PknG and 
five purchasable ATP analogues. For each analogue is reported if it is a good candidate 
as ATP analogue, which PknG mutants are tested, results of computational prediction 
and results of experimental assays. 
ATP analogues Good 
candidate 
PknG 
mutants 
Predicted 
interaction 
Experimentally 
tested 
Experimental 
validation 
N6-(methyl) 
ATP 
X - - - - 
N6-(benzyl) 
ATP 
Ѵ V211G X - - 
M232G Ѵ Ѵ Ѵ 
8-Azido ATP X - - - - 
PF9 Ѵ Y234G X - - 
V235G Ѵ Ѵ X 
7d7p ATP Ѵ M232H X - - 
M232S Ѵ Ѵ Ѵ 
M232T Ѵ Ѵ Ѵ 
 
 
An ATP analogue is a good co-substrate for an engineered kinase if it does not 
bind to the ligand-binding pocket of the wild-type kinase but just to that of the 
engineered kinase.  
Among the group of five analogues examined, N6-(methyl) ATP and 8-Azido ATP 
are inadequate candidates as ATP analogues as both ligands fit into the wild-type 
PknG ATP binding site without any clash. In N6-(methyl) ATP the methyl group is 
small enough to occupy the adenine region without any overlap whereas in 8-
Azido ATP the azido ion has access to the phosphates region (Figure 3.14 and 
3.19).  
PF9, N6-(benzyl) ATP and 7d7p ATP are good candidates as cofactors for PknG 
mutants. PF9 fits into the binding site of PknGV235G and the complex has a 
favorable predicted interaction energy (-23.3 kcal/mol). The in vitro kinase assay 
shows that PknGV235G has no significant activity with PF9 whereas its 
phosphorylation activity is very significant with native ATP, and this is true at all 
cofactor concentrations (Figure 3.21). The experimental results do not confirm our 
prediction showing that PknGV235G preferentially uses native ATP as 
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phosphodonor. To understand such disagreement, we analyzed in more details 
the structure of PknGV235G in complex with PF9 (Figure 4.1 A and B). The 
mutation of the hydrophobic Val235 into Gly allows the accommodation of the 
ligand analogue within the engineered binding pocket. Even though the 
phenylethynyl group is involved in hydrophobic interactions with Tyr234 and 
Ile157, the benzyl ring occupies the solvent accessible region of the ATP binding 
pocket that generally is not occupied by ATP and is opened to the solvent (Figure 
4.1 B). In evaluating the interaction between engineered kinases and ATP-
competitive ligands, we do not take into account the solvent. No models are used 
to simulate the solvent and its role in the protein-ligand interaction. This 
approximation could explain the favorable interaction energy we get for the 
PknGV235GPF9 complex. The scoring function only takes into consideration the 
favorable protein-ligand hydrophobic interactions and does not consider the 
unfavorable placement of the hydrophobic benzyl ring in a hydrophilic 
environment.  
 
 
Figure 4.1. A) The PknGV235G ATP binding pocket (represented as a molecular 
surface) and the PF9 conformer with best GlideScore (represented as lines). Residues 
involved in hydrophobic interactions are represented as darker molecular surface (Tyr234 
and Ile157). Gly235 (the mutated residue) is represented as stick. B) The same image 
rotated 90° with respect to A.  
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N6-(benzyl) ATP reveals a favorable interaction with PknGM232G (predicted 
energy is -24.20 kcal/mol). The in vitro kinase assay shows that at cofactor 
concentrations ranging from 50 M to 10 M there is a discrimination between the 
phosphorylation activity of PknGM232G with ATP and with N6-(benzyl) ATP. The 
engineered PknG preferentially uses the ATP-analogue as cofactor to 
phosphorylate GarA. On the other hand, wild-type PknG preferentially uses native 
ATP and this occurs at all cofactor concentrations (Figure 3.18). The experimental 
assay confirmed the in silico prediction made and those results suggested that 
PknGM232G and N6-(benzyl) ATP are good candidates for follow-up in vivo 
experiments.  
Favorable interaction energies were predicted for 7d7p ATP in complex with 
PknGM232S and PknGM232T (-10 kcal/mol and -7.03 kcal/mol, respectively). The 
gatekeeper Met232 is mutated into the smaller Ser and Thr allowing the ATP 
analogue to access the buried region of the ligand-binding pocket. The 
mutagenesis of Met into Ser and Thr not only creates an additional space within 
the binding pocket but also introduce two amino acids that can be involved in 
specific interactions (H-bonds) with the ligand analogue. The in vitro kinase assay 
shows the ability of PknGM232S and PknGM232T to use 7d7p ATP as co-
substrate in contrast to PknGM232G that preferentially uses the native ATP 
(Figure 3.28 A and B). Despite the agreement between the computational 
predictions and in vitro results for PknGM232S and PknGM232T, both mutants 
show the same preference to interact with native ATP and ATP analogue (Figure 
3.26 A and B). Those two designed pairs are thus not suitable for following in vivo 
assays.  
Our computational analysis together with the in vitro kinase assays recognize the 
PknGM232GN6-(benzyl) ATP pair as an interesting combination for following 
experimental tests. The in vitro experiment shows that PknGM232G is catalytically 
active and preferentially uses N6-(benzyl) ATP as cofactor. Therefore, using this 
designed pair might result in the experimental identification of the specific 
substrates involved in the PknG infective pathway. A similar approach provided 
the identification of cofilin and calumenin as specific v-Src substrates [20].  
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Our computational approach can be used as prescreening test in the experimental 
procedure for the kinase substrates identification. The advantage of a 
computational prescreening is that it reduces the number of experimental assays 
to perform resulting in a significant reduction of the time and the cost of the whole 
experiment. In the specific case of PknG, we computationally tested a group of 
five ATP analogues and three of them were identified as good candidates as  
ATP-competitive ligands. Of the all possible PknG mutants that would be obtained 
by mutating residues within the ligand-binding site, seven were predicted as 
potentially engineerable PknGs and only four of them are identified as interesting 
targets to experimentally test (Table 4.1). In conclusion, only four designed pairs 
were considered promising and further experimentally tested.  
 
 
4.3 Advantages and limitations of the computational protocol 
 
The main goal of our study is to engineer a protein kinase so that it is catalytic 
active and specifically uses an ATP-analogue as phosphodonor. To reach that 
goal, we used a single conformation of the target kinase derived from the crystal 
structure of a complex containing either the target protein bound to its native 
ligand or a molecule mimicking it. In case the solved structures were not available 
for the kinase of interest, a model could be built using as template the structure of 
a homologue with the features described above. At the same time, we were 
interested in ATP analogues that act as phosphodonors for engineered protein 
kinases. In short, not only ATP analogues had to adequately fit into the 
engineered binding sites but they also had to bind to those same binding sites in 
the right geometry. Each ATP derivative was modelled on the adenine, ribose and 
phosphates geometry of the native ATP within the kinase ligand-binding site, and 
for each analogue we did not take into account the total flexibility. The 
conformational space was not completely sampled. The search was performed by 
keeping fixed the adenine moiety, the ribose ring and the phosphates and by 
leaving the bonds of each substituent group free to rotate. The sample of the 
entire conformational space could provide conformers with more suitable energies 
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but catalytically useless conformations. As we were specifically looking for ATP 
analogues that bind to a given kinase and act as cofactors, the assumption of not 
considering the total flexibility for each analogue allowed the inspection of 
significant ensemble of conformers that were all potentially active as 
phosphodonors. Inactive conformations of ATP analogues were not analyzed.  
Our computational protocol explores pairings of potential mutations and ligand 
analogues. The Shokat’s method has been extensively used. Ubersax et al 
modified the gatekeeper Phe88 of the cyclin-dependent kinase CdK1 into Gly 
allowing the engineered kinase to bind to N6-(benzyl) ATP. The designed pair 
permitted to identify several Cdk1 substrates, such as the forkhead transcription 
factor Fhk2 [143]. In a similar approach, Eblen and coworkers used the mutant at 
the gatekeeper position of the extracellular signal-regulated kinase ERK2 
ERK2Q103G, and N6-(cyclopentyl) ATP to identify the nucleoporin translocated 
promoter region (TPR) as one ERK2 specific substrate [29]. In these different 
studies, the method always involved the mutagenesis of the gatekeeper position 
into Gly and N6-(substituent) ATPs with bulky hydrophobic substituent groups. 
With respect to Shokat’s method, our computational strategy did not exclusively 
focus on gatekeeper residues but instead inspected diverse residues belonging to 
the ligand-binding site to identify potential candidates for single-point mutations. 
On one hand, this allows for the possibility to generate diverse mutants for a 
target kinase. On the other hand, it permits testing ATP analogues with 
substituent groups attacked on various positions of the adenine ring and that have 
disparate chemical features. However, once a non-gatekeeper residue is 
identified as potential candidate for mutagenesis other aspects have to be 
considered. For instance, if the potential candidate belongs to the phosphates 
region, it is necessary to verify its role in the kinase catalytic activity before 
changing it into another residue. Catalytic residues, such as the highly conserved 
Lys and Asp, are not appropriate candidates considering that their mutagenesis 
would result in the disruption of the catalytic activity of the protein of interest, 
therefore generating an inactive engineered kinase. 
When the Shokat method is mainly based on the ‘bump-and-hole’ model, in our 
approach we also considered the chemical complementarity between the mutated 
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residue and the ATP derivative. In the case of PknG and 7d7p ATP, the in vitro 
experiments show that PknGM232S and PknGM232T bind to 7d7p ATP, whereas 
the pair PknGM232G7d7p ATP, designed only by using the ‘bump-and-hole’ 
approach, does not work. These results support the idea of using both shape and 
chemical complementarity in designing combinations of engineered kinases and 
chemical derivatives of ATP. Nevertheless, the fact that PknGM232S and 
PknGM232T exhibit the same phosphorylation activity in the presence of ATP and 
7d7p ATP shows that the two mutants equally bind to native ATP and ATP 
analogue. That finding suggests that the use of shape and chemical 
complementarities should be further explored. It would be interesting to design a 
pair characterized by a specific interaction between the side chain of the mutated 
residue and the substituent group of the ATP derivative. This would allow to test if 
the design of a precise protein-ligand interaction confers to the engineered protein 
the ability to specifically bind to the ATP derivative and not to the native ATP. 
A limitation of the method developed in this thesis is that it is a manual approach. 
Once a residue is identified as potential candidate for mutagenesis, we visually 
inspected the binding site to identify the amino acid that at that position could well 
interact with a given ATP analogue. The chemical space is not totally sampled as 
not all twenty amino acids are tested at a given position of the binding site. This 
prevented the possibility of exploring all possible promising mutant-ligand pairs as 
it would be performed by a systematic automated approach. 
Another drawback of our approach is that in modeling and evaluating pairs of 
engineered kinase and ATP analogue, we did not include water and its effects in 
protein-ligand binding. Water molecules play a key role in protein-ligand binding 
and to neglect them could affect the binding process, for instance by excluding 
interactions in which water molecules are involved or by considering accessible to 
the ligand an area of the binding site that indeed is involved in interaction with the 
solvent. This is the case, for instance, of the complex of PknGV235G and PF9 
when ignoring water results also in overlooking the placement of a hydrophobic 
group, the phenylethynyl within a polar environment. Therefore, we predicted a 
favorable energy of interaction that was not confirmed by in vitro experiments. A 
way to overcome such limitation might be to use theoretical approaches for 
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solvent modeling. One example is the method developed by Bottoms and 
coworkers in 2006. This method identifies hydration sites (sites where water 
molecules are located) in protein binding sites using the conservation of those 
sites across protein families [144]. Similarly, Michel and coworkers developed a 
procedure called ‘Just Add Water Molecules’ (JAWS) that allows to find the 
number and position of water sites in protein binding sites [145]. 
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5 Summary  
 
In this thesis we have successfully developed a computational protocol for 
designing pairs of engineered kinases and ATP-competitive ligands. Our method 
can be used as prescreening test in the wider experimental procedure for the 
kinase substrates identification. The reliability of the protocol was tested on 
different tyrosine and serine/threonine protein kinases from the scientific literature 
where Shokat’s method was applied and experimental data were available. On 
one side the protocol provided a relative rank of suitable ATP analogues for a 
given engineered kinase, on the other hand it provided a way to evaluate for a 
given ATP-competitive ligand which mutations within the kinase binding site would 
be compatible. The method successfully correlated with published experimental 
data and this suggested the possibility to apply it on a new system for which no 
data were available.  
We applied our protocol to the Mtb PknG. The identification of Mtb PknG 
downstream substrates would address the open questions concerning its mode of 
action and its role in the survival of the pathogen within the host organism. We 
tested five purchasable ATP analogues. Four pairs were identified being 
promising combinations of mutation in the PknG binding site and ATP derivative 
and were further tested in in vitro assays. The ability of a PknG mutant to 
preferentially use an ATP analogue as phosphodonor, was confirmed only by one 
pair, PknGM232GN6-(benzyl) ATP. That pair is the analogue to the Shokat 
classic pair, where the gatekeeper residue is mutated to Gly and the ATP 
analogue has a hydrophobic group at position N6 of the adenine ring. Different 
pairs computationally identified (PknGV235G-PF9, PknGM232S7d7p ATP and 
PknGM232T7d7p ATP) were not confirmed promising by in vitro testes 
PknGM232GN6-(benzyl) ATP is currently tested in an ex vivo context by the 
group of the Prof. J. Pieters, at Biozentrum. With results obtained in this study, we 
hope to clarify the pathway regulated by PknG and help in the development of 
new therapies to combat such infectious diseases.  
 
91 
 
References 
 
1. Zhang, W.H., G. Otting, and C.J. Jackson, Protein engineering with unnatural 
amino acids. Current Opinion in Structural Biology, 2013. 23(4): p. 581-587. 
2. Saven, J.G., Computational protein design: engineering molecular diversity, 
nonnatural enzymes, nonbiological cofactor complexes, and membrane proteins. 
Curr Opin Chem Biol, 2011. 15(3): p. 452-7. 
3. Li, X., Z. Zhang, and J. Song, Computational enzyme design approaches with 
significant biological outcomes: progress and challenges. Comput Struct 
Biotechnol J, 2012. 2: p. e201209007. 
4. Tiwari, M.K., et al., Computational approaches for rational design of proteins with 
novel functionalities. Comput Struct Biotechnol J, 2012. 2: p. e201209002. 
5. Li, Y. and P.C. Cirino, Recent advances in engineering proteins for biocatalysis. 
Biotechnology and Bioengineering, 2014. 111(7): p. 1273-1287. 
6. Kaplan, J. and W.F. DeGrado, De novo design of catalytic proteins. Proc Natl 
Acad Sci U S A, 2004. 101(32): p. 11566-70. 
7. Lazar, G.A., et al., Engineered antibody Fc variants with enhanced effector 
function. Proc Natl Acad Sci U S A, 2006. 103(11): p. 4005-10. 
8. Cochran, F.V., et al., Computational de novo design and characterization of a 
four-helix bundle protein that selectively binds a nonbiological cofactor. Journal of 
the American Chemical Society, 2005. 127(5): p. 1346-1347. 
9. Richter, F., et al., De Novo Enzyme Design Using Rosetta3. PLoS One, 2011. 
6(5). 
10. Rothlisberger, D., et al., Kemp elimination catalysts by computational enzyme 
design. Nature, 2008. 453(7192): p. 190-5. 
11. Jiang, L., et al., De novo computational design of retro-aldol enzymes. Science, 
2008. 319(5868): p. 1387-91. 
12. Siegel, J.B., et al., Computational design of an enzyme catalyst for a 
stereoselective bimolecular Diels-Alder reaction. Science, 2010. 329(5989): p. 
309-13. 
13. Schreier, B., et al., Computational design of ligand binding is not a solved 
problem. Proceedings of the National Academy of Sciences of the United States 
of America, 2009. 106(44): p. 18491-18496. 
14. Baker, D., An exciting but challenging road ahead for computational enzyme 
design. Protein Sci, 2010. 19(10): p. 1817-9. 
92 
 
15. Hanks, S.K. and T. Hunter, Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification. FASEB journal : 
official publication of the Federation of American Societies for Experimental 
Biology, 1995. 9(8): p. 576-96. 
16. Cheng, H.C., et al., Regulation and function of protein kinases and phosphatases. 
Enzyme Res, 2011. 2011: p. 794089. 
17. Shah, K., et al., Engineering unnatural nucleotide specificity for Rous sarcoma 
virus tyrosine kinase to uniquely label its direct substrates. Proceedings of the 
National Academy of Sciences of the United States of America, 1997. 94(8): p. 
3565-70. 
18. Liu, Y., et al., Engineering Src family protein kinases with unnatural nucleotide 
specificity. Chem Biol, 1998. 5(2): p. 91-101. 
19. Liu, Y., et al., A molecular gate which controls unnatural ATP analogue 
recognition by the tyrosine kinase v-Src. Bioorganic & Medicinal Chemistry, 1998. 
6(8): p. 1219-26. 
20. Shah, K. and K.M. Shokat, A chemical genetic screen for direct v-Src substrates 
reveals ordered assembly of a retrograde signaling pathway. Chem Biol, 2002. 
9(1): p. 35-47. 
21. Cravatt, B.F., Kinase chemical genomics--a new rule for the exceptions. Nature 
Methods, 2005. 2(6): p. 411-2. 
22. Bucci, M., C. Goodman, and T.L. Sheppard, A decade of chemical biology. Nature 
Chemical Biology, 2010. 6(12): p. 847-854. 
23. Dephoure, N., et al., Combining chemical genetics and proteomics to identify 
protein kinase substrates. Proc Natl Acad Sci U S A, 2005. 102(50): p. 17940-5. 
24. Kraybill, B.C., et al., Inhibitor scaffolds as new allele specific kinase substrates. 
Journal of the American Chemical Society, 2002. 124(41): p. 12118-12128. 
25. Larochelle, S., et al., Dichotomous but stringent substrate selection by the dual-
function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol, 2006. 
13(1): p. 55-62. 
26. Hindley, A.D., et al., Engineering the serine/threonine protein kinase Raf-1 to 
utilise an orthogonal analogue of ATP substituted at the N6 position. FEBS letters, 
2004. 556(1-3): p. 26-34. 
27. Habelhah, H., et al., Identification of new JNK substrate using ATP pocket mutant 
JNK and a corresponding ATP analogue. J Biol Chem, 2001. 276(21): p. 18090-5. 
93 
 
28. Juris, S.J., et al., Identification of otubain 1 as a novel substrate for the Yersinia 
protein kinase using chemical genetics and mass spectrometry. Febs Letters, 
2006. 580(1): p. 179-183. 
29. Eblen, S.T., et al., Identification of novel ERK2 substrates through use of an 
engineered kinase and ATP analogs. Journal of Biological Chemistry, 2003. 
278(17): p. 14926-14935. 
30. Berg, J.M., J.L. Tymoczko, and L. Stryer, Biochemistry. 5th ed. 2002, New York: 
W.H. Freeman. xxxviii, 974, [72] p. 
31. Knighton, D.R., et al., Crystal-Structure of the Catalytic Subunit of Cyclic 
Adenosine-Monophosphate Dependent Protein-Kinase. Science, 1991. 
253(5018): p. 407-414. 
32. Scheeff, E.D., et al., Structure of the Pseudokinase VRK3 Reveals a Degraded 
Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding 
Site. Structure, 2009. 17(1): p. 128-138. 
33. Huse, M. and J. Kuriyan, The conformational plasticity of protein kinases. Cell, 
2002. 109(3): p. 275-82. 
34. Hubbard, S.R. and J.H. Till, Protein tyrosine kinase structure and function. Annu 
Rev Biochem, 2000. 69: p. 373-98. 
35. Boggon, T.J. and M.J. Eck, Structure and regulation of Src family kinases. 
Oncogene, 2004. 23(48): p. 7918-27. 
36. Fang, Z., C. Grutter, and D. Rauh, Strategies for the selective regulation of 
kinases with allosteric modulators: exploiting exclusive structural features. ACS 
Chem Biol, 2013. 8(1): p. 58-70. 
37. Cheek, S., H. Zhang, and N.V. Grishin, Sequence and structure classification of 
kinases. J Mol Biol, 2002. 320(4): p. 855-81. 
38. Traxler, P. and P. Furet, Strategies toward the design of novel and selective 
protein tyrosine kinase inhibitors. Pharmacol Ther, 1999. 82(2-3): p. 195-206. 
39. Vulpetti, A. and R. Bosotti, Sequence and structural analysis of kinase ATP pocket 
residues. Farmaco, 2004. 59(10): p. 759-65. 
40. Mao, L., et al., Molecular determinants for ATP-binding in proteins: a data mining 
and quantum chemical analysis. J Mol Biol, 2004. 336(3): p. 787-807. 
41. Cappello, V., A. Tramontano, and U. Koch, Classification of proteins based on the 
properties of the ligand-binding site: the case of adenine-binding proteins. 
Proteins, 2002. 47(2): p. 106-15. 
94 
 
42. Babor, M., V. Sobolev, and M. Edelman, Conserved positions for ribose 
recognition: importance of water bridging interactions among ATP, ADP and FAD-
protein complexes. Journal of molecular biology, 2002. 323(3): p. 523-32. 
43. Klebe, G. and T. Mietzner, A fast and efficient method to generate biologically 
relevant conformations. J Comput Aided Mol Des, 1994. 8(5): p. 583-606. 
44. Adams, J.A., Kinetic and catalytic mechanisms of protein kinases. Chem Rev, 
2001. 101(8): p. 2271-90. 
45. Xu, W., et al., Crystal structures of c-Src reveal features of its autoinhibitory 
mechanism. Mol Cell, 1999. 3(5): p. 629-38. 
46. Zuccotto, F., et al., Through the "gatekeeper door": exploiting the active kinase 
conformation. Journal of medicinal chemistry, 2010. 53(7): p. 2681-94. 
47. Huang, D., et al., Kinase selectivity potential for inhibitors targeting the ATP 
binding site: a network analysis. Bioinformatics, 2010. 26(2): p. 198-204. 
48. Noble, M.E.M., J.A. Endicott, and L.N. Johnson, Protein kinase inhibitors: insights 
into drug design from structure. Science (New York, N Y ), 2004. 303(5665): p. 
1800-5. 
49. Azam, M., et al., Activation of tyrosine kinases by mutation of the gatekeeper 
threonine. Nat Struct Mol Biol, 2008. 15(10): p. 1109-18. 
50. Elphick, L.M., et al., Using chemical genetics and ATP analogues to dissect 
protein kinase function. Acs Chemical Biology, 2007. 2(5): p. 299-314. 
51. B©œhm, H.-J. and G. Schneider, Protein-ligand interactions from molecular 
recognition to drug design. 2003, Weinheim: Wiley-VCH. xx, 242 p. 
52. Tsai, N., Wolfson, Maizel and ussinov, Protein–Ligand Interactions: Energetic 
Contributions and Shape Complementarity. Encyclopedia of life sciences, 2001. 
53. Kuriyan, J., B. Konforti, and D. Wemmer, The molecules of life : physical and 
chemical principles. xxii, 1008 pages. 
54. Bronowska, A.K., Thermodynamics of Ligand-Protein Interactions: Implications for 
Molecular Design H.I.f.T.S. Heidelberg, Editor. 2011. 
55. Gohlke, H. and G. Klebe, Approaches to the description and prediction of the 
binding affinity of small-molecule ligands to macromolecular receptors. 
Angewandte Chemie (International ed in English), 2002. 41(15): p. 2644-76. 
56. Bissantz, C., B. Kuhn, and M. Stahl, A medicinal chemist's guide to molecular 
interactions. J Med Chem, 2010. 53(14): p. 5061-84. 
57. SanjavNilapwar, Characterization and Exploitation of Protein Ligand Interactions 
for Structure Based Drug Design. 2009, University College London  
95 
 
58. Lodish, H.F., et al., Molecular cell biology. Seventh edition, International edition / 
ed. xxxiii, 1154, G-26, I-31 pages. 
59. Jeffrey, G.A., An introduction to hydrogen bonding. Topics in physical chemistry. 
1997, New York ; Oxford: Oxford University Press. vii, 303 p. 
60. Dubey, K.D., R.K. Tiwari, and R.P. Ojha, Recent advances in protein-ligand 
interactions: molecular dynamics simulations and binding free energy. Curr 
Comput Aided Drug Des, 2013. 9(4): p. 518-31. 
61. Gilson, M.K. and H.X. Zhou, Calculation of protein-ligand binding affinities. Annu 
Rev Biophys Biomol Struct, 2007. 36: p. 21-42. 
62. Jorgensen, W.L., The many roles of computation in drug discovery. Science, 
2004. 303(5665): p. 1813-8. 
63. Berman, H.M., et al., The Protein Data Bank. Acta Crystallographica Section D-
Biological Crystallography, 2002. 58: p. 899-907. 
64. Allen, F.H., The Cambridge Structural Database: a quarter of a million crystal 
structures and rising. Acta Crystallogr B, 2002. 58(Pt 3 Pt 1): p. 380-8. 
65. Kitchen, D.B., et al., Docking and scoring in virtual screening for drug discovery: 
methods and applications. Nat Rev Drug Discov, 2004. 3(11): p. 935-49. 
66. Huang, S.-Y., S.Z. Grinter, and X. Zou, Scoring functions and their evaluation 
methods for protein-ligand docking: recent advances and future directions. 
Physical chemistry chemical physics : PCCP, 2010. 12(40): p. 12899-908. 
67. Huang, S.Y. and X. Zou, Advances and challenges in protein-ligand docking. Int J 
Mol Sci, 2010. 11(8): p. 3016-34. 
68. Neudert, G. and G. Klebe, DSX: a knowledge-based scoring function for the 
assessment of protein-ligand complexes. J Chem Inf Model, 2011. 51(10): p. 
2731-45. 
69. Muegge, I. and Y.C. Martin, A general and fast scoring function for protein-ligand 
interactions: a simplified potential approach. J Med Chem, 1999. 42(5): p. 791-
804. 
70. DeWitte, R.S. and E.I. Shakhnovich, SMoG: de Novo design method based on 
simple, fast, and accurate free energy estimates .1. Methodology and supporting 
evidence. Journal of the American Chemical Society, 1996. 118(47): p. 11733-
11744. 
71. Friesner, R.A., et al., Glide: a new approach for rapid, accurate docking and 
scoring. 1. Method and assessment of docking accuracy. J Med Chem, 2004. 
47(7): p. 1739-49. 
96 
 
72. Wang, R., L. Lai, and S. Wang, Further development and validation of empirical 
scoring functions for structure-based binding affinity prediction. J Comput Aided 
Mol Des, 2002. 16(1): p. 11-26. 
73. Bohm, H.J., The development of a simple empirical scoring function to estimate 
the binding constant for a protein-ligand complex of known three-dimensional 
structure. J Comput Aided Mol Des, 1994. 8(3): p. 243-56. 
74. Goodsell, D.S., et al., Automated docking in crystallography: analysis of the 
substrates of aconitase. Proteins, 1993. 17(1): p. 1-10. 
75. Shoichet, B.K., A.R. Leach, and I.D. Kuntz, Ligand solvation in molecular docking. 
Proteins, 1999. 34(1): p. 4-16. 
76. Verdonk, M.L., et al., Improved protein-ligand docking using GOLD. Proteins-
Structure Function and Genetics, 2003. 52(4): p. 609-623. 
77. Morris, G.M., et al., Automated docking using a Lamarckian genetic algorithm and 
an empirical binding free energy function. Journal of Computational Chemistry, 
1998. 19(14): p. 1639-1662. 
78. Ewing, T.J., et al., DOCK 4.0: search strategies for automated molecular docking 
of flexible molecule databases. J Comput Aided Mol Des, 2001. 15(5): p. 411-28. 
79. Lindorff-Larsen, K., et al., Improved side-chain torsion potentials for the Amber 
ff99SB protein force field. Proteins, 2010. 78(8): p. 1950-8. 
80. Cornell, W.D., et al., A second generation force field for the simulation of proteins, 
nucleic acids, and organic molecules (vol 117, pg 5179, 1995). Journal of the 
American Chemical Society, 1996. 118(9): p. 2309-2309. 
81. Jorgensen, W.L. and J. Tiradorives, The Opls Potential Functions for Proteins - 
Energy Minimizations for Crystals of Cyclic-Peptides and Crambin. Journal of the 
American Chemical Society, 1988. 110(6): p. 1657-1666. 
82. Kaminski, G.A., et al., Evaluation and reparametrization of the OPLS-AA force 
field for proteins via comparison with accurate quantum chemical calculations on 
peptides. Journal of Physical Chemistry B, 2001. 105(28): p. 6474-6487. 
83. Ponder, J.W. and D.A. Case, Force fields for protein simulations. Protein 
Simulations, 2003. 66: p. 27-+. 
84. Aqvist, J., V.B. Luzhkov, and B.O. Brandsdal, Ligand binding affinities from MD 
simulations. Acc Chem Res, 2002. 35(6): p. 358-65. 
85. Aqvist, J., C. Medina, and J.E. Samuelsson, A new method for predicting binding 
affinity in computer-aided drug design. Protein engineering, 1994. 7(3): p. 385-91. 
97 
 
86. Srinivasan, J., et al., Continuum solvent studies of the stability of DNA, RNA, and 
phosphoramidate - DNA helices. Journal of the American Chemical Society, 1998. 
120(37): p. 9401-9409. 
87. Gohlke, H., C. Kiel, and D.A. Case, Insights into protein-protein binding by binding 
free energy calculation and free energy decomposition for the Ras-Raf and Ras-
RalGDS complexes. Journal of molecular biology, 2003. 330(4): p. 891-913. 
88. Yuk, J.-M. and E.-K. Jo, Host immune responses to mycobacterial antigens and 
their implications for the development of a vaccine to control tuberculosis. Clinical 
and experimental vaccine research, 2014. 3(2): p. 155-67. 
89. Perkins, M., Development, testing and introduction of new diagnostic tools for 
tuberculosis, in Tuberculosis. 2014, Henry Stewart Talks: London. p. 1 online 
resource (1 streaming video file (35 min.). 
90. Abubakar, I., et al., Tuberculosis 2013:5 Drug-resistant tuberculosis: time for 
visionary political leadership. Lancet Infectious Diseases, 2013. 13(6): p. 529-539. 
91. Walburger, A., et al., Protein kinase G from pathogenic mycobacteria promotes 
survival within macrophages. Science, 2004. 304(5678): p. 1800-1804. 
92. Nguyen, L. and J. Pieters, The Trojan horse: survival tactics of pathogenic 
mycobacteria in macrophages. Trends in cell biology, 2005. 15(5): p. 269-276. 
93. Warner, D.F. and V. Mizrahi, The survival kit of Mycobacterium tuberculosis. 
Nature Medicine, 2007. 13(3): p. 282-284. 
94. Cole, S.T., et al., Deciphering the biology of Mycobacterium tuberculosis from the 
complete genome sequence. Nature, 1998. 393(6685): p. 537-+. 
95. Av-Gay, Y. and M. Everett, The eukaryotic-like Ser/Thr protein kinases of 
Mycobacterium tuberculosis. Trends Microbiol, 2000. 8(5): p. 238-44. 
96. Cowley, S., et al., The Mycobacterium tuberculosis protein serine/threonine kinase 
PknG is linked to cellular glutamate/glutamine levels and is important for growth in 
vivo. Molecular microbiology, 2004. 52(6): p. 1691-1702. 
97. Scherr, N., et al., Structural basis for the specific inhibition of protein kinase G, a 
virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A, 2007. 
104(29): p. 12151-6. 
98. O'Hare, H.M., et al., Regulation of glutamate metabolism by protein kinases in 
mycobacteria. Molecular microbiology, 2008. 70(6): p. 1408-1423. 
99. Durocher, D. and S.P. Jackson, The FHA domain. FEBS Lett, 2002. 513(1): p. 58-
66. 
98 
 
100. England, P., et al., The FHA-containing protein GarA acts as a phosphorylation-
dependent molecular switch in mycobacterial signaling. Febs Letters, 2009. 
583(2): p. 301-307. 
101. Barthe, P., et al., Dynamic and Structural Characterization of a Bacterial FHA 
Protein Reveals a New Autoinhibition Mechanism. Structure, 2009. 17(4): p. 568-
578. 
102. Liu, Y., et al., Structural basis for selective inhibition of Src family kinases by PP1. 
Chem Biol, 1999. 6(9): p. 671-8. 
103. Sastry, G.M., et al., Protein and ligand preparation: parameters, protocols, and 
influence on virtual screening enrichments. J Comput Aided Mol Des, 2013. 27(3): 
p. 221-34. 
104. Kirchmair, J., et al., The Protein Data Bank (PDB), its related services and 
software tools as key components for in silico guided drug discovery. Journal of 
medicinal chemistry, 2008. 51(22): p. 7021-40. 
105. Xie, X., et al., Crystal structure of JNK3: a kinase implicated in neuronal 
apoptosis. Structure, 1998. 6(8): p. 983-91. 
106. Schindler, T., et al., Crystal structure of Hck in complex with a Src family-selective 
tyrosine kinase inhibitor. Mol Cell, 1999. 3(5): p. 639-48. 
107. Kinoshita, T., et al., Structure of human Fyn kinase domain complexed with 
staurosporine. Biochem Biophys Res Commun, 2006. 346(3): p. 840-4. 
108. Levinson, N.M., et al., A Src-like inactive conformation in the abl tyrosine kinase 
domain. PLoS Biol, 2006. 4(5): p. e144. 
109. Rellos, P., et al., Structure of the CaMKIIdelta/calmodulin complex reveals the 
molecular mechanism of CaMKII kinase activation. PLoS Biol, 2010. 8(7): p. 
e1000426. 
110. Schulze-Gahmen, U., H.L. De Bondt, and S.H. Kim, High-resolution crystal 
structures of human cyclin-dependent kinase 2 with and without ATP: bound 
waters and natural ligand as guides for inhibitor design. Journal of medicinal 
chemistry, 1996. 39(23): p. 4540-6. 
111. Shewchuk, L., et al., Binding mode of the 4-anilinoquinazoline class of protein 
kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to 
cyclin-dependent kinase 2 and p38 kinase. J Med Chem, 2000. 43(1): p. 133-8. 
112. Sali, A. and T.L. Blundell, Comparative protein modelling by satisfaction of spatial 
restraints. J Mol Biol, 1993. 234(3): p. 779-815. 
99 
 
113. Lombana, T.N., et al., Allosteric activation mechanism of the Mycobacterium 
tuberculosis receptor Ser/Thr protein kinase, PknB. Structure, 2010. 18(12): p. 
1667-77. 
114. Benkert, P., S.C. Tosatto, and D. Schomburg, QMEAN: A comprehensive scoring 
function for model quality assessment. Proteins, 2008. 71(1): p. 261-77. 
115. Chang, G., W.C. Guida, and W.C. Still, An Internal Coordinate Monte-Carlo 
Method for Searching Conformational Space. Journal of the American Chemical 
Society, 1989. 111(12): p. 4379-4386. 
116. Biasini, M., et al., OpenStructure: an integrated software framework for 
computational structural biology. Acta Crystallogr D Biol Crystallogr, 2013. 69(Pt 
5): p. 701-9. 
117. Poznanski, J., A. Poznanska, and D. Shugar, A Protein Data Bank survey reveals 
shortening of intermolecular hydrogen bonds in ligand-protein complexes when a 
halogenated ligand is an H-bond donor. PLoS One, 2014. 9(6): p. e99984. 
118. De Colibus, L., et al., More-powerful virus inhibitors from structure-based analysis 
of HEV71 capsid-binding molecules. Nature structural & molecular biology, 2014. 
21(3): p. 282-8. 
119. Miller, B.R., et al., MMPBSA.py: An Efficient Program for End-State Free Energy 
Calculations. Journal of Chemical Theory and Computation, 2012. 8(9): p. 3314-
3321. 
120. D.A. Case, T.A.D., T.E. Cheatham, III, C.L. Simmerling, J. Wang, R.E. Duke, R., 
et al., AMBER 12, S.F. University of California, Editor. 2012. 
121. Wang, J., et al., Automatic atom type and bond type perception in molecular 
mechanical calculations. J Mol Graph Model, 2006. 25(2): p. 247-60. 
122. Darden, T., D. York, and L. Pedersen, Particle Mesh Ewald - an N.Log(N) Method 
for Ewald Sums in Large Systems. Journal of Chemical Physics, 1993. 98(12): p. 
10089-10092. 
123. Ryckaert, J.P., G. Ciccotti, and H.J.C. Berendsen, Numerical-Integration of 
Cartesian Equations of Motion of a System with Constraints - Molecular-Dynamics 
of N-Alkanes. Journal of Computational Physics, 1977. 23(3): p. 327-341. 
124. Gohlke, H. and D.A. Case, Insights into protein-protein binding by binding free 
energy calculation and free energy decomposition using a generalized born 
model. Abstracts of Papers of the American Chemical Society, 2003. 225: p. 
U791-U791. 
100 
 
125. Wang, J.M., T.J. Hou, and X.J. Xu, Recent Advances in Free Energy Calculations 
with a Combination of Molecular Mechanics and Continuum Models. Current 
Computer-Aided Drug Design, 2006. 2(3): p. 287-306. 
126. Jayaram, B., D. Sprous, and D.L. Beveridge, Solvation free energy of 
biomacromolecules: Parameters for a modified generalized born model consistent 
with the AMBER force field. Journal of Physical Chemistry B, 1998. 102(47): p. 
9571-9576. 
127. Onufriev, A., D. Bashford, and D.A. Case, Exploring protein native states and 
large-scale conformational changes with a modified generalized born model. 
Proteins-Structure Function and Bioinformatics, 2004. 55(2): p. 383-394. 
128. Kollman, P.A., et al., Calculating structures and free energies of complex 
molecules: Combining molecular mechanics and continuum models. Accounts of 
Chemical Research, 2000. 33(12): p. 889-897. 
129. Hermann, R.B., Theory of Hydrophobic Bonding .2. Correlation of Hydrocarbon 
Solubility in Water with Solvent Cavity Surface-Area. Journal of Physical 
Chemistry, 1972. 76(19): p. 2754-&. 
130. Massova, I. and P.A. Kollman, Combined molecular mechanical and continuum 
solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspectives in 
Drug Discovery and Design, 2000. 18: p. 113-135. 
131. Hunter, J.D., Matplotlib: A 2D graphics environment. Computing in Science & 
Engineering, 2007. 9(3): p. 90-95. 
132. van der Walt, S., S.C. Colbert, and G. Varoquaux, The NumPy Array: A Structure 
for Efficient Numerical Computation. Computing in Science & Engineering, 2011. 
13(2): p. 22-30. 
133. Scherr, N., et al., Survival of pathogenic mycobacteria in macrophages is 
mediated through autophosphorylation of protein kinase G. Journal of 
bacteriology, 2009. 191(14): p. 4546-54. 
134. Shah, K., et al., Engineering unnatural nucleotide specificity for Rous sarcoma 
virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci U S 
A, 1997. 94(8): p. 3565-70. 
135. Hanke, J.H., et al., Discovery of a novel, potent, and Src family-selective tyrosine 
kinase inhibitor - Study of Lck- and FynT-dependent T cell activation. Journal of 
Biological Chemistry, 1996. 271(2): p. 695-701. 
101 
 
136. Notredame, C., D.G. Higgins, and J. Heringa, T-Coffee: A novel method for fast 
and accurate multiple sequence alignment. Journal of Molecular Biology, 2000. 
302(1): p. 205-217. 
137. Simpson, R.J., Proteins and Proteomics: A Laboratory Manual. 
138. Homeyer, N. and H. Gohlke, Free Energy Calculations by the Molecular 
Mechanics Poisson-Boltzmann Surface Area Method. Molecular Informatics, 
2012. 31(2): p. 114-122. 
139. Okimoto, N., et al., High-performance drug discovery: computational screening by 
combining docking and molecular dynamics simulations. PLoS Comput Biol, 2009. 
5(10): p. e1000528. 
140. Rastelli, G., et al., Fast and Accurate Predictions of Binding Free Energies Using 
MM-PBSA and MM-GBSA. Journal of Computational Chemistry, 2010. 31(4): p. 
797-810. 
141. Tian, C., et al., The stereoselectivity of CYP2C19 on R- and S-isomers of proton 
pump inhibitors. Chem Biol Drug Des, 2014. 83(5): p. 610-21. 
142. Liu, Y., et al., Engineering Src family protein kinases with unnatural nucleotide 
specificity. Chemistry & biology, 1998. 5(2): p. 91-101. 
143. Ubersax, J.A., et al., Targets of the cyclin-dependent kinase Cdk1. Nature, 2003. 
425(6960): p. 859-864. 
144. Bottoms, C.A., T.A. White, and J.J. Tanner, Exploring structurally conserved 
solvent sites in protein families. Proteins, 2006. 64(2): p. 404-21. 
145. Michel, J., J. Tirado-Rives, and W.L. Jorgensen, Prediction of the water content in 
protein binding sites. J Phys Chem B, 2009. 113(40): p. 13337-46. 
146. Finn, R.D., et al., Pfam: the protein families database. Nucleic Acids Res, 2014. 
42(Database issue): p. D222-30. 
147. Roderick E Hubbard, M.K., Hydrogen Bonds in Proteins: Role and Strength. 
Encyclopedia of life sciences, 2010. 
148. Israelachvili, J. and R. Pashley, The Hydrophobic Interaction Is Long-Range, 
Decaying Exponentially with Distance. Nature, 1982. 300(5890): p. 341-342. 
 
 
102 
 
A Appendix 
A.1 Sum of vdW radii 
 
Table A.1. Sum of vdW radii for the most common protein-ligand atom pairs in case of  
non-halogenated ligands. 
Atom pairs Sum of vdW radii (Å) 
C-C 3.4 
C-N 3.25 
C-S 3.5 
C-O 3.22 
C-P 3.50 
N-N 3.1 
N-S 3.35 
N-O 3.07 
N-P 3.35 
O-S 3.32 
O-O 3.04 
O-P 3.32 
S-P 3.60 
S-S 2.03 
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A.2 Ribose and phosphates conformations 
 
The evaluation of the interaction between kinase mutants and ATP-competitive 
ligands was performed by GlideScore. We decided to score only the substituted 
adenine base of each analogue and not the ribose ring and the phosphates within 
the binding pocket of an engineered kinase. This approximation is based on the 
fact that the position and the orientation of the planar adenine moiety within the 
binding site is conserved among almost all serine/threonine and tyrosine protein 
kinases. This is due to the highly conserved H-bonds between the adenine ring 
and two protein residues. On the other hand, both the ribose ring and the 
phosphates can assume various conformations in different protein kinases. This is 
due to their intrinsic flexibility and to the protein environment, such as the 
presence of water molecules within the binding site or of divalent ions and the way 
of interaction with specific residues. To verify the accuracy of the approximation, 
we analyzed the geometries of ATPs and ATPs-like (ADP, AMP, ACP, AGS and 
ANP) within the ligand-binding pocket of serine/threonine and tyrosine protein 
kinases for which crystal structures had been solved. We built a dataset 
containing 258 entries (Table A.2.1). Each entry represents the crystal structure of 
the kinase domain of a serine/threonine or a tyrosine protein kinase bound to ATP 
or an ATP-like ligand. Two databases were used to build our dataset, the Protein 
families database, Pfam [146] and the Protein Data Bank, PDB [63]. In Pfam we 
performed two searches, one using the accession code PF00069 (that identify 
protein kinase domains) and the other one using the accession code PF07714 
(that identify protein tyrosine kinases). Those searches identified 2157 entries. In 
the PDB we performed four searches, two using the Pfam codes PF00069 and 
PF07714 and two using the keywords ‘serine/threonine protein kinase’ and 
‘tyrosine protein kinase’. In that manner we identified 1229 structures. Then, we 
compared entries obtained from Pfam and PDB in order to eliminate redundant 
structures. Then, we only consider structures of kinase domains bound to ATP or 
ATP-like ligands together with at least one divalent ion and not to other molecules 
(such as kinase inhibitors). We superposed the ligand binding sites of all 258 
structures to check the geometries of the diverse cofactors within the binding 
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pockets. Figure A.2.1 represents the binding site superposition of 10 structures 
belonging to the dataset.  
 
 
Figure A.2.1. Structural superposition of the binding sites of 10 protein kinase structures 
(PDBs: 1ATP, 1B38, 1B39, 1CSN, 1HCK, 1PHK, 1QL6, 3E8N, 3Q53 and 3DKC).  
 
 
The structural superposition shows that the position and the orientation of the 
adenine moieties within the different binding sites are highly conserved. On the 
other hand, the ribose rings and the phosphates assume diverse conformations, 
positions and orientations within the diverse binding sites. Figure A.2.2 A and B 
represents the binding site of the Mus musculus cAMP-dependent protein kinase 
in complex with ATP and Mn2+ (PDB: 1ATP) and of the human cyclin-dependent 
kinase 2 in complex ATP and Mg2+ (PDB: 1B38). The position and the orientation 
of the two adenine moieties is conserved in both kinases where they are involved 
in H-bonds with protein residues. The ribose rings show two different 
conformations and phosphates shows two different geometries as consequence 
of different interactions. In cAMP-dependent protein kinase  and  phosphates 
coordinate the Mn2+ and the catalytic Lys interacts with  and  phosphates. In 
cyclin-dependent kinase 2 the Mg2+ is coordinated by the  and  phosphates and 
the catalytic Lys interacts with the  phosphate. 
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Figure A.2.2. ATP binding site of cAMP-dependent protein kinase (PDB: 1ATP) and 
cyclin-dependent kinase 2 (PDB: 1B38). Yellow dashed lines represent protein-ligand H-
bonds and red dashed lines represent interaction between phosphates and divalent ions, 
Mn2+ in violet and Mg2+ in green. Red stars indicate catalytic Lys. 
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Table A.2.1. PDB entries of our dataset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1ATP 
1B38 
1B39 
1CSN 
1FIN 
1FQ1 
1GOL 
1GY3 
1H1W 
1HCK 
1JST 
1OL6 
1PHK 
1Q24 
1Q97 
1QL6 
1QMZ 
1RDQ 
1S9I 
1S9J 
1U5R 
1UA2 
1ZYD 
2BIY 
2CCH 
2CCI 
2CJM 
2IJM 
2P55 
2PHK 
2Y4I 
2YAA 
3A7H 
3A8W 
3BLQ 
3BU5 
3C4W 
3C4X 
3DKC 
3DV3 
3DY7 
3E7E 
3E8N 
3EQB 
3FJQ 
3GNI 
3HMN 
3HRC 
3HRF 
3KMW 
3OS3 
3PP1 
2QO9 
2QOC 
2QOQ 
2R5T 
2SRC 
2V55 
2VWB 
2VWI 
2WTK 
2XRW 
2XS0 
2Y9Q 
2ZV8 
3A99 
3ALN 
3ALO 
3BEG 
3COK 
3DAK 
3DFC 
3EHA 
3F5U 
3FHI 
3FXX 
3G51 
3GT8 
3GU4 
3GU5 
3HKO 
3HX4 
3IDB 
3IDC 
3IGO 
3IS5 
3JUH 
3KN5 
3KU2 
3LIJ 
3LLT 
3MFR 
3MFS 
3MFU 
3MIA 
3NIE 
3NSZ 
3O7L 
3ORN 
3PFQ 
3PVB 
3Q4Z 
3Q5I 
3SLS 
3U87 
3UIM 
3VJN 
3VJO 
4DFX 
4DG0 
4EKK 
1DS5 
1YXU 
2IVT 
2YAB 
3C0H 
3DLZ 
3DQX 
3GC0 
3NYO 
1MRU 
2G2F 
2PMI 
2W5B 
3DQW 
3EQC 
3EQD 
3FZP 
3ORI 
3ORK 
3ORL 
3ORM 
3ORO 
3ORP 
3ORT 
1J1C 
1JBP 
1L3R 
1MP8 
1MQ4 
1NY3 
1OL5 
1OL7 
1PKG 
1Q8Y 
1WBP 
2B9F 
2B9H 
2B9I 
2B9J 
2CN5 
2F9G 
2G2I 
2QUR 
2RIO 
2W4J 
 2W4K 
2W5A 
2WQE 
2WQN 
2XUU 
3A7J 
3BRB 
3C4Z 
3C50 
3C51 
3D5W 
3DLS 
3EH9 
3EQG 
3EQH 
3EQI 
3F5G 
3F61 
3G2F 
3GU6 
3GU7 
3LJ0 
3MBL 
3NIZ 
3P23 
3QC9 
3QHR 
3QHW 
3TNQ 
1I44 
1K3A 
1O6Y 
1U54 
2PVF 
2PVY 
2PWL 
2PY3 
2PZ5 
2PZP 
2PZR 
2Q0B 
2Z7Q 
3CLY 
3GQI 
3KEX 
3LMG 
3PLS 
1JPA 
2HEN 
3LCT 
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A.3 Visualization of protein-ligand complexes 
 
All protein-ligand complexes of this thesis are visually inspected in Maestro 
(version 9.5, Schrödinger, LLC, New York, NY, 2013). Protein-ligand contacts are 
identified using the following formula: 
 
21
12
RR
D
C

  (A.1) 
 
where 12D  is the distance between atoms 1 and 2, ,1R  and 2R  are the van der 
Waals radii of atoms 1 and 2. Protein-ligand contacts are good when distances 
are within the attractive range of potential and as atoms get closer the quality of 
their contacts gets worse. When the distance between two atoms is lower than 
0.89 Å the protein-ligand contact is defined as ‘bad’ whereas if the distance is 
lower than 0.75 Å the contact is defined as ‘ugly’.  
The H-bonds are identified by the acceptor-donor (A-D) distance and angle. The 
cut off for the A-D distance is 4.0 Å and the A-D angle must be greater than 120 ° 
[147]. 
The hydrophobic interactions are identified by measuring the distance between 
two carbon atoms and 4.0 Å is the max distance of carbon atoms for an 
hydrophobic interaction [148]. 
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A.4 Pairs of residues within JNK binding site 
 
Table A.4.1 shows all pairs of residues within the JNK ligand-binding site 
identified as good candidates for double mutagenesis to enlarge the binding site. 
 
Table A.4.1. Pairs of JNK residues identified as good candidates for double mutagenesis 
to allow the accommodation of four ATP analogues (N6-(benzyl) ATP, N6-(2-phenythyl) 
ATP, N6-(cyclopentyl) ATP and N6-(1-methylbutyl) ATP). In red are residue pairs mutated 
in the work of Habelhah and coworkers [27]. 
ATP analogues Residues pairs within JNK ligand-binding site 
N6-(benzyl) ATP Met111-Ile86, Met111-Glu109, Met108-Leu168, Ile86-Leu168, 
Ile86-Glu109, Ile86-Met111, Val158-Leu168, Glu109-Ala53, 
Glu109-Met111, Ala53-Met111 
N6-(2-phenythyl) ATP Met111-Ile86, Met108-Leu168, Ile86-Val158, Ile86-Leu168, 
Ile86-Glu109, Ile86-Met111, Val158-Leu168, Glu109-Leu110, 
Glu109-Ala53 Glu147-Met111, Leu110-Ala53, Ala53-Met111 
N6-(cyclopentyl) ATP Met111-Ile86, Met108-Leu168, Ile86-Glu109, Ile86-Met111, 
Ala53-Met111 
N6-(1-methylbutyl) ATP Met111-Ile86, Met111-Glu109, Met108-Leu168, Ile86-Val158, 
Ile86-Leu168, Ile86-Glu109, Ile86-Met108, Glu109-Met108, 
Ala53-Met108 
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